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ABSTRACT
TRANSMURAL HETEROGENEITY OF CELLULAR LEVEL CARDIAC
CONTRACTILE PROPERTIES IN AGING AND HEART FAILURE
The left ventricle of the heart relaxes when it fills with blood and contracts to eject
blood into circulation to meet the body’s metabolic demands. Dysfunction in
either relaxation or contraction of the left ventricle can lead to heart failure.
Transmural heterogeneity is thought to contribute to normal ventricular wall
motion but it is not well understood how transmural modifications affect the failing
left ventricle. The overall hypothesis of this dissertation is that normal left
ventricles exhibit transmural heterogeneity in cellular level contractile properties
and with aging and heart failure there are region-specific changes in cellular level
contractile mechanisms.
Age is the biggest risk factor associated with heart failure and therefore we
investigated transmural changes in Ca2+ handling and contractile proteins in
aging F344 rats before the onset of heart failure. We found that in 22-month old
F344 rats there is a region-specific decrease in cardiac troponin I
phosphorylation in the sub-epicardium that may contribute to slowed myocyte
relaxation in the sub-epicardial cells of the same age.
We then investigated the transmural patterns of contractile properties in
myocardial tissue samples from patients with heart failure. Force and power
output reduced most significantly in the samples from the mid-myocardial region
when compared to sub-epicardium and sub-endocardium of the failing hearts.
There was a region-specific increase in fibrosis is the mid-myocardium of the
failing hearts. Myocardial power output was correlated with key sarcomeric
proteins including cardiac troponin I, desmin and myosin light chain-1.
The results in this dissertation reveal novel region-specific modifications in
contractile properties in aging and heart failure. These transmural effects can
potentially contribute to disruption in normal wall motion and lead to ventricular
dysfunction

KEYWORDS: transmural heterogeneity, left ventricle, human biospecimens,
sarcomere, heart failure
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Chapter 1. Introduction

1.1. Heart is a heterogeneous organ
William Harvey, a 17th century physician, was one of the first to describe the
heart as a muscular organ. He proposed that the function of the heart was to
expel blood from the ventricles through contraction and relaxation. He described
these findings in his book titled “On the motion of the heart and blood in animals”
in 1628 1. Physician Richard Lower built upon Harvey’s work and described the
anatomy of the heart in further detail in his book titled “ Tractatus de corde” in
1669 2. He observed a complex arrangement of muscle fibers that formed
“layers” and he speculated that the architectural complexity of the fibers were
potentially important in the ejection of blood from the ventricles (Figure 1.1) 2. In
the 19th century, James Pettigrew did an exhaustive study of the heart anatomy
in several vertebrates and found that the muscle “layers” could be peeled from
the outside (sub-epicardium) of the left ventricle to the inside (sub-endocardium)
of the left ventricular chamber. He observed that the fiber directions changed with
every muscle “layer” he removed 3. Intriguingly, the fibers in the middle “layers”
were observed to be circumferentially arranged and were called “triebwerkzeug”
which in the German language can be translated to “actuating fibers” because it
was thought that these fibers were potentially important for ventricular ejection 4.
These historical observations about the muscle “layers” and fiber angles were
further supported in a study done by Streeter et al. in 1969 5. In this study, they
dissected a through-wall transmural piece of the left ventricular wall and then
1

histologically sliced them into 10 μm sections. This quantitative study showed
that the muscle fiber arrangement shifted from -90° (relative to right-hand
orientation) in the sub-epicardium, to ~0° in the mid-myocardium
(circumferentially arranged fibers) to +90° in the sub-endocardium of the canine
left ventricular wall (Figure 1.2 5). Similar muscle “layers” and fiber angles were
reported in human left ventricles in a study done by Greenbaum et al. in 1981 6.
All these observations from the past several centuries provide support for the
distinct myocardial architecture across the ventricular wall. In the last 10 years
sophisticated technologies like magnetic resonance diffusion tensor imaging are
being used to visualize in detail the myocardial architecture and fiber angles in
the ventricles 7. Furthermore, several studies have linked structural heterogeneity
in myocardial architecture across the left ventricular wall to the function of the
heart. For example, cardiac imaging and computational modeling of the heart
have shown that transmural myocardial heterogeneity can influence wall
thickening, ejection fraction (volume fraction of blood pumped out of the ventricle
with each heart beat) 8 and ventricular torsion (an index of the “wringing” motion
of the heart) 9, 10. Assessing myocardial heterogeneity in terms of cardiac function
can be extremely useful when understanding human heart failure.

1.1.1. Heart failure and the left ventricular wall
Heart failure is a debilitating clinical syndrome in which the ventricles are unable
to pump sufficient blood to meet the body’s metabolic demands. Currently, there
are 5.1 million people in the United States who suffer from this syndrome. This
2

population is on the rise because advancing age is the number one risk factor for
heart failure and 1 in 5 Americans will be >65 years of age by 2050 11.
The progression of heart failure is classified into stages A through D by the
American College of Cardiology Foundation (ACCF) and American Heart
Association (AHA) and/or stages I through IV by New York Heart Association
(NYHA). ACCF/AHA classification provides information about the progression of
structural changes in the heart and NYHA classification yields information about
the diminishing ability of patients to carry out physical activities. Some of the
symptoms of heart failure are shortness of breath, fatigue and edema 11.
Heart failure can be divided into 2 groups-systolic heart failure and diastolic heart
failure. In systolic heart failure the heart is not able to maintain cardiac output
because of reduced ejection fraction (≤ 40%). In diastolic heart failure the
ejection fraction is preserved (≥ 50%) but patients exhibit symptoms of heart
failure such as, shortness of breath. Currently, it is much more difficult to
diagnose diastolic heart failure but it is estimated that half of the patients with
heart failure have diastolic dysfunction 11-13.
There are several causes of heart failure, which include hypertension, ischemia,
genetic mutations (mutations in at least 10 sarcomeric genes have been
identified) 14-16 or the cause maybe idiopathic (unknown) 11. Even though the
etiologies are varied there are common pathophysiological changes that occur in
heart failure, called ventricular remodeling. Due to the complex nature of
ventricular remodeling a consensus statement was released in the Journal of the
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American College of Cardiology stating “Cardiac remodeling may be defined as
genome expression, molecular, cellular and interstitial changes that are
manifested clinically as changes in size, shape and function of the heart after
cardiac injury” 17.
Ventricular remodeling can be adaptive at first but with progression of heart
failure it can become maladaptive 17, 18. Depending on the stressors there can
either be concentric hypertrophy (thickening of the left ventricular wall by addition
of myocytes in parallel) or cardiac dilation/eccentric hypertrophy (thinning of the
left ventricular wall through alignment of myocytes in series and enlargement of
the ventricular chamber) 19, 20 (Figure 1.3). Any of these modifications can
potentially affect the ventricular wall transmurally 21.

1.1.1.1. End-stage heart failure
There are ~50,000 patients with end-stage heart failure (classified as stage D or
IV) at any given time in the United States. These patients have structural heart
disease (mostly severely dilated ventricles 13, Figure 1.3) and are unable to
carryout any physical activity 11. These patients generally have an ejection
fraction of ≤ 20% 13. At this stage the options for therapy are few and involve
chronic inotropes, mechanical circulatory support and/or heart transplant surgery
11, 22.

Due to the limited number of available donors there are only ~ 2300 heart

transplants each year 11.
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1.1.2. Imaging studies evaluating transmural ventricular wall function
It is not fully understood how the left ventricle changes transmurally during heart
failure. There are some imaging studies that have shown changes in fiber angle
orientation 23, 24 with heart failure. For example, a study induced a myocardial
infract in sheep and after 3 months excised the hearts and evaluated the hearts
using diffusion tensor imaging. The authors showed that the mid-myocardial and
the sub-epicardial fibers were disorganized and there were changes in fiber
angles 25 that could ultimately lead to pump dysfunction.
In a quest to find better prognostic tools, several clinical studies in patients with
cardiac dysfunction have shown that the shortening of the middle transmural
region (p=0.001) of the ventricular wall is a better predictor of cardiovascular
death, myocardial infarction and stroke than shortening of the endocardial region
(p=0.089) and the gold standard ejection fraction (p=0.085) (Table 1.1 26). These
results are surprising because ejection fraction (a measure of global ventricular
function used in standard clinical practice) was not a good predictor of clinical
end-points when compared to midwall shortening, which is an indicator of
ventricular wall motion. These imaging studies have shown that transmural
effects are clinically important and may potentially be of better prognostic value in
predicting clinical endpoints 26-30. However, the underlying mechanisms that give
rise to these transmural effects are still unclear and may include tissue, cellular
and molecular level heterogeneity in the ventricular wall.

5

1.1.2.1. Transmural tissue level changes in the ventricular wall
The myocardium is predominantly made up of myocytes and cardiac
fibroblasts 31. Cardiac fibroblasts are essential for extracellular matrix protein
production and become hyperactive after injury or stress, which leads to fibrosis.
Collagen protein makes up ~80% of the extra cellular matrix 31. With heart failure
there maybe an increase in fibrosis 31, 32, replacement of myocytes with fibrotic
tissue and myocyte disarray 18, 33, 34. These modifications can have detrimental
effect on both the electrical and mechanical activity of the heart. For example
studies have shown that discontinuities due to fibrosis can lead to conduction
abnormalities and arrhythmias 34-36. The replacement of myocytes with fibrotic
tissue can also reduce the number of force generating sarcomeres, which can
ultimately lead to reduction in contractile function 37.
Recent clinical studies have investigated the effect of the regional distribution of
fibrosis through the ventricular wall and its effect on myocardial contractile
properties using late gadolinium enhancement cardiovascular magnetic
resonance. They found that midwall fibrosis may predict adverse cardiovascular
outcomes in patients with cardiac dysfunction 38-40. These studies allude to a
region dependent increase in fibrosis. However, few studies have investigated
the regional distribution of fibrosis across the left ventricular wall and its effect on
cellular level contractile properties.

6

1.1.3. Cellular and molecular level transmural heterogeneity
Previous studies have demonstrated that there are distinct differences in action
potential morphologies and action potential duration between the subepicardium, mid-myocardium and sub-endocardium of the left ventricles in
various mammals including humans 41. In heart failure there can be a reduction in
the difference between the transmural action potential duration across the
ventricular wall leading to arythmogenesis 42, 43. Some of these changes are due
to modifications in expression of several cardiac transporters and ion channels
across the ventricular wall 44.
There are few reports in the animal-based literature which show that different
regions of the left ventricular wall exhibit variable contractile properties 45 46 47.
van der Velden et al. 47 isolated sub-epicardial and sub-endocardial samples from
the left ventricular wall of pig hearts 3 weeks after an induced myocardial
infraction or a sham operation. They found that maximum force decreased by
35% in the sub-endocardial samples in the myocardial infract group when
compared to sub-endocardial samples in the sham group.
In summary, the heart is a heterogeneous organ evidenced by transmural
differences in myocardial architecture and fiber angles 2-5. There are also cellular
and molecular level differences which contribute to transmural differences in
excitation of the left ventricular wall 36, 42-44. However, transmural changes that
may contribute to cellular level contraction have not been explored in aging and
human heart failure.
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1.2. Sarcomere function in the heart

1.2.1. Contraction and sarcomeric proteins
Sarcomeres are basic units of muscle, organized in series and in parallel in the
cytosol of a myocyte. They are made up of thick and thin filaments, which slide
past each other to undergo contraction 48, 49 (Figure 1.4). The z-disks of a
sarcomere contains many different proteins including desmin, an intermediate
filament protein which acts as a scaffold and connects sarcomeres at z-disks 50.
Six titin proteins (the biggest protein in the human body, ~33 MDa) span from the
z-disk to the m-line of the sarcomere 51.
The cross bridge is a hexamer made up of two myosin heavy chains (MHC)
whose tails polymerize with each other to form the thick filament. Attached to a
MHC neck region are two proteins called the myosin light chain-1 (MLC-1) and
myosin light chain-2 (MLC-2). On the head region of a MHC is an ATP binding
site 52, 53 (Figure 1.4).
The thin filament is made up of a polymerized actin backbone. Tropomyosin a
filamentous protein winds itself around every 7th actin on the thin filament and
blocks the actin binding sites from myosin in the relaxed state 54. Bound to
tropomyosin is the troponin complex, which is made up of cardiac troponin T
(cTnT) that binds to tropomyosin, cardiac troponin I (cTnI) which is the inhibitory
unit that keeps actin and tropomyosin in place in the relaxed state, and cardiac
troponin C (cTnC) which is the Ca2+ binding subunit 55 (Figure 1.4).
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Before contraction can occur Ca2+ is released from the sarcoplasmic reticulum
and binds to cTnC. This leads to a conformational change in cTnI which removes
its inhibition and allows tropomyosin to move and expose the binding sites on
actin for myosin to attach 56. Myosin hydrolyzes ATP and binds to actin and
undergoes a power stroke sliding the thin and thick filaments past each other
causing contraction. After contraction has occurred Ca2+ in taken up by the
sarcoplasmic reticulum through the sarcoplasmic reticulum Ca2+-ATPase
(SERCA) pump and thin filament proteins go back to their relaxed state. At the
same time ATP binds to myosin allowing myosin to go back to its relaxed state 48,
49, 52, 56.

1.2.2. Mechanics of the heart
The heart must perform work against an afterload on a beat-to-beat basis to
maintain cardiac output. This is not an easy task because ventricular filling and
ejection is not uniform for every beat. The heart is able to correct for these
changes due to the Frank-Starling mechanism (Figure 1.5). This mechanism is
the intrinsic ability of the heart to change the force of contraction and therefore
cardiac output in response to alteration (increase or decrease) in the end
diastolic volume 57.
At the myocyte level, preload (the volume of blood during ventricular filling)
stretches the myocytes, which in turn increase the sarcomere length. In this
phase cytosolic Ca2+ concentration is ~100 nM and there are very few thick and
thin filaments interactions. During contraction the Ca2+ concentration increase
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upto ~1 μM which leads to thin filament activation 58. At this phase cross bridges
are able to attach to actin and undergo a power stroke leading to myocyte
shortening and force production. This action allows the heart to generate power
and perform work against an afterload (aortic pressure) 55, 59.
The process of contraction and relaxation are made of active and passive
mechanical components. The active mechanical component is primarily due to
the interaction of myosin motors on the thick filament with actin on the thin
filament 60, 61. The passive component is primarily due the sarcomeric protein titin
and extracellular matrix protein collagen 62.
Furthermore, preload, afterload and contractility can all affect the Frank-Starling
mechanism (Figure 1.5) of the heart and are highly regulated through alteration
in content, isoform switch and posttranslational modifications of sarcomeric
proteins 63. Therefore, dysfunction in sarcomeric proteins can lead to mechanical
pump dysfunction 63 and thus contribute to diastolic and/or systolic heart failure.
The modification in sarcomeric proteins and its functional consequence will be
discussed further in Chapter 3, 4 and 5.

1.3. Overall hypothesis and scope of this dissertation
The overall hypothesis of this dissertation is that normal left ventricles exhibit
transmural heterogeneity in cellular level contractile properties and with aging
and heart failure there are region-specific changes in cellular level contractile
mechanisms.
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In Chapter 3, we investigate the adaptive limits of myocytes before the onset of
heart failure in a rodent model of aging. We evaluate the biochemical status of
proteins that are involved in Ca2+ handling and contraction from the subepicardium, mid-myocardium and sub-endocardium of the left ventricular free
wall of aging F344 rats.
In Chapter 4, we investigate the mechanical properties of ventricular samples
from patients with end-stage heart failure where the hearts had already become
maladaptive. Functional measurements were performed in chemically
permeabilized multicellular preparations. These biospecimens were optimal for
testing myofibrillar-level function and for investigating the effects of the
extracellular matrix on passive mechanical properties. We also investigate
biochemical status of sarcomeric proteins and the extent of fibrosis in throughwall left ventricular samples from the sub-epicardium, mid-myocardium and subendocardium of non-failing and failing human hearts.
In summary, we used both rodents and human biospecimens to investigate
cellular and molecular modifications that affect properties involved in both
relaxation and contraction across the ventricular wall to understand cellular level
transmural effects in aging and end-stage heart failure.
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Table 1.1. Predictors of cardiovascular endpoints.
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Figure 1.1. An illustration of the spiral myocardial fibers.
A sketch of the spiral myocardial fibers observed by Richard Lower from the
anterior side of the heart (Figure 4, adapted from the book
“Tractatus de corde”, 1669 2).
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Figure 1.2. Photomicrographs of histological sections and fiber angles.
Typical sequence of photomicrographs showing fiber angles in successive
sections taken from a heart in systole. The sections are parallel to the epicardial
plane. Fiber angle is +90° at the endocardium, running through 0° at the midwall
to -90° at the epicardium. The sequence of numbers refers to deciles of wall
thickness (left panel). Fiber angles for four sampling sites, a through d, in section
from a heart in diastole are plotted as a function of percent wall thickens. Zero
percent of wall thickness implies the endocardial surface. M represents the mean
of the data at these four sites. (Figure 3 and 4, adapted from Street et al.1969 5)
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Figure 1.3. Pathological changes with progression of heart failure.
Dilated (left) and hypertrophied (right) heart showing left ventricular remodeling.

15

16

Figure 1.4. Sarcomere.
Schematics of the major sarcomeric proteins.
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Figure 1.5. Frank-Starling mechanism of the heart.
The curves show the change in cardiac output for a given ventricular diastolic
volume when there is increased contractility (dark blue curve), in a normal resting
heart (green curve) and in a failing heart (red curve).

Copyright © Premi Haynes 2014
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Chapter 2. Methods

2.1. Animal model and human cardiac tissue

2.1.1. Aging F344 rats
Female Fischer 344 rats were obtained from the National Institute on Aging
colony maintained by Harlan (Indianapolis, IN). The rats purchased were of 6, 18,
and 22 months of age (n=3 animals per age group). All animal procedures were
approved by the University of Kentucky Institutional Animal Care and Use
Committee and conformed to standards of the Guide for the Care and Use of
Laboratory Animals.
We harvested the heart from each animal by first injecting heparin (800 U IP) and
then anesthetizing each animal with an intraperitoneal injection of pentobarbital
(50 mg/kg). We dissected the chest wall to expose the thoracic cavity and
excised the heart rapidly. This heart was then cannulated at the aorta and the
coronary arteries were perfused with ice-cold Krebs Henseleit solution (in
mmol/L: 113 NaCl, 4.7 KCl, 0.6 KH2PO4, 1.2 MgSO4, 12 NaHCO3, 10 KHCO3,
10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES], 30 Taurine, 5.5
glucose, and 10 2,3-butanedione monoxime [BDM]) until the perfusate ran clear
of blood from the coronaries.
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The heart were then hung from a Langendorff perfusion apparatus and
enzymatically digested for 10–12 min at 37°C with digestion solution (Krebs
Henseleit containing 10 mM BDM, 20 μM CaCl2, and 46 μg/ml Liberase TH,
Roche Applied Science, Indianapolis, IN). After the initial digestion step, the left
ventricular free wall was dissected and sectioned transmurally into three portions
of equal thickness (sub- epicardium, mid-myocardium, and sub- endocardium),
Figure 2.1 64. These tissues were then flash frozen in liquid nitrogen and then
stored in -80°C for biochemical assays.
A separate set of F344 animals of ages 6, 18 and 22 months were used to
assess left ventricular function using echocardiography. These animals were
later sacrificed and the hearts were excised and perfused in the same fashion as
mentioned above but were not flash frozen. Tissues from the three different
regions were digested further and single myocytes were isolated. Ca2+ transients
and unloaded shortening contractions were measured using electrically-excitable
myocytes from the sub-epicardial, mid-myocardial and sub-enodcardial regions
of the hearts. A computational model was also generated to predict how the
sarcomere length of an unloaded myocyte would change in response to an
intracellular Ca2+ transient 65. These set of experiments were not a part of this
dissertation but the results were used to make inferences about the biochemical
results from the F344 aging rats.
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2.1.2. Human cardiac biospecimens

2.1.2.1. Procurement and cryo-preservation of biospecimens
We obtained ventricular through-wall samples from patients undergoing heart
transplants at the University of Kentucky and from organ donors who did not
have prior history of heart failure through the Kentucky Organ Donors Affiliates
(KODA). Figure 2.2 shows an external view of one donor and one failing human
heart. We cut left ventricular tissue sections from the free wall just above the
apex as soon as the heart was excised from the body by the surgeon and was
passed to us. We then transported the tissue to the laboratory in specimen cups
containing saline slush. We split the tissue sections transmurally into three parts
of equal thickness to form the sub-epicardial, mid-myocardial and subendocardial samples. These specimens were then placed in 2 mL cryogenic
vials, flash-frozen in liquid nitrogen, and subsequently stored at -150°C in the
vapor phase of liquid nitrogen. All procedures were approved by the University of
Kentucky Institutional Review Board and subjects gave informed consent.

2.1.2.2. Clinical characteristics of patients and donors
We studied left ventricular tissue from patients in end-stage heart failure
receiving heart transplants and from organ donors. We had 5 patients with nonischemic and 5 with ischemic heart failure in this study. The mean age of the
patients with heart failure was 49 (range 20 to 65) while that of the organ donors
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was 35 (range 18 to 59). Females donated 20% of the failing hearts and 50% of
the non-failing organs. Data describing the patients and donors are shown in
Table 2.2.

2.2. Muscle mechanics
We performed mechanical assays on chemically permeabilized multicellular
preparations obtained from human hearts. We analyzed a total of 141
multicellular preparations from 48 samples (3 transmural regions from each of 6
non-failing and 10 failing human hearts). Jweied et al. showed that previously
frozen and fresh tissue samples yield comparable data with these techniques 66.
We saved the permeabilized samples that were not used for functional tests for
subsequent biochemical assays. Following sub-sections describe the overview of
the procedures to prepare and perform these biophysical assays.

2.2.1. Solutions
We used relaxing solution to isolate multicellular preparations that contained (in
mmol L-1): 100 KCl, 10 imidazole, 4 ATP, 2 EGTA and 5 MgCl2 and two protease
inhibitors (phenylmethylsulfonide 500 µmol L-1 and leupeption 40 µmol L-1). We
used pCa (= -log10[Ca2+]) solutions for the mechanical experiments which
contained (in mmol L-1): 20 imidazole, 14.5 creatine phosphate, 7 EGTA, 4
MgATP, 1 free Mg2+, free Ca2+ ranging from 1 nmol L-1 (pCa 9.0) to 32 µmol L-1
(pCa 4.5) and sufficient KCl to adjust the ionic strength to 180 mmol L-1. The
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precise composition of each pCa solution was determined using Maxchelator
software (version 2.50) and NIST stability constants 67.

2.2.2. Chemically permeabilized multicellular preparations
We obtained multicellular cardiac preparations as previously described for rat
samples 68. We took frozen tissue specimens (~5 x 5 x 5 mm) acquired using the
methods mentioned in section 2.1.2.1 and placed it in 10 ml of relaxing solution
(see section 2.2.1 for solutions). We then mechanically disrupted the tissue using
a tissue homogenizer (Polytron, Brinkman Instruments, Westbury, NY), and
chemically permeabilized the tissue using Triton X-100 (30 min, 1% v/v). We then
stored the permeabilized samples in relaxing solution at 4°C for upto 12 hours
before use (Figure 2.3).

2.2.3. Mechanical assays with varying Ca2+concentrations
We attached individual preparations (Figure 2.4) between a force transducer
(resonant frequency 600 Hz, model 403, Aurora Scientific, Aurora, Ontario,
Canada) and a servo motor (step time 0.6 ms, model 312B, Aurora) by crimping
their ends into metal troughs (shaped from 27 gauge tubing) with overlays of 4-0
nylon monofilament as previously illustrated in Figure 1B of Campbell & Moss 69
(Figure 2.3). The experimental temperature was 15°C. We stretched the sample
in pCa 9.0 solution (see section 2.2.1 for solutions) by manually adjusting the
manipulator holding the motor until the mean sarcomere length of the preparation
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(measured by video microscopy) was within 1% of 2.20 µm. We estimated the
cross-sectional area (2.17 ± 0.07 x 10-8 m2) from the video images by assuming
that each preparation had a circular profile. Once the sarcomere length was set
the average length of the preparations was calculated to be 688 ± 11 µm. If it is
assumed that single human myocytes 70 have average dimensions of 100 x 25 x
25 µm, and that the relative collagen content of the preparations ranged from 5 to
58%, each myocardial preparation probably contained between 13 and 30 single
myocytes.
Initially each preparation was immersed in pCa 4.5 solution to maximally activate
the sample. Once tension had attained steady-state, we subjected the muscle to
3 ‘saw-tooth’ lengthening/shortening perturbations (magnitude 0.04 l0, velocity of
0.12 l0 s-1, inter-perturbation interval 100 ms, where l0 is the muscle length) and a
rapid shortening/re-stretch maneuver (0.2 l0, 20 ms duration) before it was
returned to pCa 9.0 solution (Figure 2.5). This protocol has been described
previously 68, 71. We subsequently performed similar trials for each preparation
using solutions with pCa values ranging from 9.0 to 5.0.

2.2.3.1. Tension-pCa curves
Tension-pCa curves were generated with isometric force values measured in
these trials and by fitting the raw data to an equation of the form
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where A corresponds to passive force, B represents Ca2+ activated force, n is the
2+
 is the free Ca2+ concentration required to develop
Hill coefficient, and Ca50

half the maximum Ca2+-dependent force.

2.2.3.2. Rate of tension recovery
After the rapid shortening/re-stretch maneuver, the rate of tension recovery (ktr)
was calculated by fitting a single exponential function to the recovery time-course
as -ln(1/2)/(t1/2), where t1/2 is the time required for tension to rise from the Presid
to 1/2(Pmax + Presid) and where Pmax is the maximum tension attained after
restretch. Presid was defined as the minimum tension occurring after restretch
(Figure 2 of Campbell, 2006 72).

2.2.3.3. Short-range force and short-range stiffness
Short-range force and short-range stiffness values were calculated for each
stretch response at each level of Ca2+ activation. The short-range force is the
non-linear force response due to strained cross bridges when the preparation is
stretched by 4% of the original length at a speed of 0.12 l0 s-1after the preparation
reached steady state. Short-range force was determined using the algorithm
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illustrated in Figure 2A of Mitov et. al., 2009 68. Short-range stiffness values are
expressed as Young’s Moduli and were calculated by fitting regression lines to
the force responses measured during imposed 4% length changes 68.

2.2.4. Force-velocity assays
Once we completed the measurements at intermediate Ca2+ levels
(section 2.2.3), the preparation was re-activated in the pCa 4.5 solution. After
force had reached the steady-state for this condition, we initiated a sequence of
trials in which the preparation was allowed to shorten for 75 ms against a variety
of pre-set loads (Figure 2.6A). This technique was used to establish the
preparation’s force-velocity curve. We determined the shortening velocity for
each trial from the slope of a regression line fitted to the final 50 ms of the force
clamp 73. The average r2 value for these lines was 0.991 which indicates that the
velocity of interfilamentary movement was not markedly dependent on the total
distance shortened 74, 75.
A hyperbolic curve was fitted to the force-velocity data using Hill’s equation

( F + a ) ⋅ (V + b ) =

( F0 + a ) ⋅ b

(2)

where F is the force at shortening velocity V, and F0 is the maximum isometric
force 76. The constants a and b have dimensions of force and velocity
respectively. Power values were calculated as the product of force and velocity
(Figure 2.6B).
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We performed all mechanical tests using SLControl software 77. We performed
curve-fitting and data analysis using custom software written in MATLAB
(Mathworks, Natick, MA).

2.3. Histology
We evaluated the relative collagen content of human myocardial tissue studied in
this work by picrosirius red staining and bright field imaging 78.
The tissue samples were first transferred from long-term storage in the vapor
phase of liquid nitrogen to a cryostat maintained at -26°C. The samples were
then placed in 10 x 10 x 5 mm cryomolds and were covered with optimal cutting
temperature (OCT) medium (Schaumburg, IL). We then cut the samples into 10
µm sections and air dried them on glass slides for 1 hour at room temperature.
The staining method used was similar to the one described by Hanley et al. 79.
The slides were initially covered in Bouin’s fixative solution and incubated at 56ºC
for an hour. Next, we rinsed the slides in deionized water and placed them for 2
hours in a 0.1% Sirius red solution (w/v) dissolved in 1.3% saturated picric acid.
We then washed the slides with 0.5% acetic acid, dehydrated in 95% and 100%
ethanol, and finally equilibrated them in xylene 79. We then imaged the sections,
which had an average cross-sectional area of ~16 mm2 in bright field 78 with a
10x objective (Olympus BX61VS microscope) and analyzed the images using
custom software written in MATLAB (The Mathworks, Natick, MA). For this work
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we analyzed a total of 150 images (1-6 images from each region of each heart) in
duplicate by observers who were blinded to the experimental groups.

2.4. Biochemical assays

2.4.1. Assessment of Ca2+ handling and sarcomeric proteins modified by
aging in the myocardium of F344 rats

2.4.1.1. Phosphorylation of sarcomeric proteins
We examined the relative phosphorylation of selected sarcomeric proteins MLC2, cTnI, cTnT, and tropomyosin using gel electrophoresis (n = 3 animals/age
group). We prepared the samples by homogenizing small pieces of ventricular
tissue (described in section 2.1.1) in a urea-thiourea sample buffer (in mol L−1,
8 Urea, 2 Thiourea, 0.075 M DTT, and 0.05 Tris-HCl, with 3% SDS w/v, pH 6.8)
80.

We measured the protein concentration in each sample using a Lowry protein

assay (RC-DC kit, Bio-Rad, Hercules, CA). We then modified each sample by
adding 0.03% Bromophenol blue and 30% glycerol before boiling it at 95°C for 3
min and subsequently cooling it on ice. We then loaded precast polyacrylamide
gels (Mini-Protean TGX 10%, 15-well combs, Bio-Rad) with 3 μl of each sample
(protein concentration 1 μg/μl) and ran the gel at 200 V for 30 min. We stained
each gel with Pro-Q Diamond phosphoprotein gel stain (Invitrogen, Carlsbad,
CA), scanned the gel using a Typhoon Trio+ imager (GE Healthcare, Piscataway,
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NJ), restained the gel with SYPRO Ruby (Invitrogen), and finally scanned the gel
again. We quantified the phosphorylation levels by integrating the densitometry
profile (ImageQuant TL software, GE Healthcare) of each band in the Pro-Q
Diamond image and dividing that result by the corresponding integral calculated
for the SYPRO Ruby stained image. We calculated relative phosphorylation
levels for the different samples by normalizing to data obtained using an external
control 81 myocardial sample that was run on each gel and which was
subsequently expressed relative to the data for a single 6-month-old epicardial
sample.

2.4.1.2. Content of α- and β-MHC isoforms
We determined the relative content of the α- and β-MHC isoforms in the tissue
homogenates using gel electrophoresis. As described by Tikunov 82, we
extracted myosin from the tissue homogenates using a buffer containing 100 mM
KCl, 100 mM KH2PO4, 50 mM K2HPO4, 10 mM EDTA, 10 mM
Na4P2O7·10H2O, 4 mM β-Mercaptoethanol and 5% (vol/vol) Triton X-100 (pH
6.5, 4–8°C, 100-μl volume, 24 h). We then added Laemmli buffer (80 μl) to each
sample, after which it was heated to 95°C for 4 min. We then resolved the treated
samples using gels that were 60 × 80 × 0.75 mm and contained 7% acrylamide
(50:1 with bis-Acrylamide) and 35% glycerol. We ran these gels at a constant
current of 3.0 mA for ∼18 h at 4°C and subsequently silver stained the gels with

a commercial kit (SilverStain Plus, Bio-Rad). We then obtained scanned images
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using a conventional office scanner (V500 Photo, Epson, Long Beach, CA). We
determined the relative content of each isoform by fitting the densitometry
profiles with asymmetrical Gaussian functions using GelBandFitter software
previously developed by our laboratory 83.

2.4.1.3. Expression of SERCA2a
In order to assess the expression of sarco-/endoplasmic reticulum Ca2+ ATPase
(SERCA2a), we first took 4 μl of each sample (Urea-Thiourea sample buffer; 1
μg/μl protein concentration) and loaded them onto precast polyacrylamide gels
(Mini-Protean TGX 4–15%, 15-well combs, Bio-Rad). We ran each gel at 200 V
for 30 min and subsequently transferred them onto a polyvinylidene difluoride
membrane using a semi-dry transfer cell. We then probed the membrane with an
antibody (sc-8094, Santa Cruz Biotechnology) to SERCA2a at a 1:1,000
dilution

84.

We then incubated the membrane with a fluorescent secondary

antibody (Alexa Fluor 680 donkey anti-goat IgG, Life Technologies) at a 1:7,500
dilution. Immunoblotted bands were visualized using a LI-COR Odyssey imaging
system (LI-COR Biosciences, Lincoln, NE) and analyzed using Odyssey version
3.0 software. As described above for the analysis of myofibrillar proteins, we
calculated relative SERCA2a contents by normalizing to data from an external
control sample that was run on each gel and subsequently expressed relative to
the data for a single 6-month epicardial sample. This facilitated statistical
analysis of data from multiple western blots.
30

2.4.2. Assessment of sarcomeric proteins modified by heart failure in
humans
We spun down and froze in eppendorf tubes, chemically permeabilized
specimens that had been prepared for functional testing but were not used for
that purpose for future biochemical assays. A total of 48 samples were
biochemically analyzed in this study (3 regions from 6 non-failing and 10 failing
hearts).
Some posttranslational modifications are thought to be regulated on a beat to
beat basis in living myocardium and may thus be sensitive to the precise
experimental conditions 85. However, the biochemical data we reported here
should be representative of the preparations that were analyzed in the functional
measurements.

2.4.2.1. Phosphorylation and content of sarcomeric proteins
The relative content (titin, myosin, cMyBP-C, α-actinin, desmin, actin, cTnI, MLC1, and MLC-2 and phosphorylation status (titin, cMyBP-C, desmin, cTnI, MLC-1)
of key sarcomeric proteins were evaluated using SDS-PAGE.
We homogenized the samples in a urea-thiourea sample buffer and determined
the protein concentration in the sample using a Lowry protein assay. We loaded
precast polyacrylamide gels (Tris-HCl, 26 well, Bio-Rad, Hercules, CA) with
samples containing 1 µg of protein. We ran each gel at 200 V for 55 minutes and
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then stained them to assess phosphoproteins using Pro-Q Diamond stain and
then re-stained with SYPRO Ruby to assess total protein content (as described
in section 2.4.1.1). We calculated relative phosphorylation levels and relative
protein contents by normalizing to data obtained for a non-failing sub-epicardial
sample that was loaded onto every gel as a control 65.

2.4.2.2. Assessment of titin isoform content and phosphorylation
The relative contents and phosphorylation levels of the N2B and N2BA isoforms
of titin was assessed using a vertical agarose gel system 86. The gel was cast
using 1.2% w/v Sea Kem Gold Agarose, 30% v/v Glycerol, 0.05 M Tris-base,
0.384 M Glycine, and 0.1% w/v SDS. We loaded the samples (3 µL at a protein
concentration of 1 µg µL-1) on the gels and ran the gels at 4°C at a constant
voltage of 40 V for the first 3hours, and then at 70 V for ~4 hours. We stained the
gels with Pro-Q Diamond and SYPRO Ruby and analyzed them as described in
section 2.4.1.1. We calculated relative phosphorylation levels and relative protein
contents by normalizing to data obtained for a non-failing sub-endocardial
sample that was loaded onto every gel as a control.

2.4.2.3. Assessment of myosin heavy chain isoform content
We assessed the relative expression of α- and β-MHC using specialized gels
cast as described in section 2.4.1.2. We loaded the samples (3 µL at a protein
concentration of 1 µg µL-1) made with urea-thiourea sample buffer onto the gels.
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We used atrial samples as positive controls. We stained the gels with SYPRO
Ruby stain for total protein and imaged and analyzed the gels as described in
section 2.4.1.2.

2.4.3. Site-specific phosphorylation of proteins
We performed immunoblotting to assess the site-specific phosphorylation of cTnI
and cMyBP-C. We performed experiments investigating the phosphorylation of
cTnI at Ser23/24 using commercially available antibodies 87 (PSer23/24, antibody
# 4004, Cell Signaling Technologies, Danvers, MA; cTnI, sc-52266, Santa Cruz,
Dallas, TX). The antibodies we used to assess site-specific phosphorylation of
cMyBP-C at Ser-273, Ser-282, and Ser-302 have been described by Govindan et
al. 88.
We ran samples (3 µL volume, at a protein concentration of 1 µg µL-1) on 10%
precast polyacrylamide gels (Mini-Protean TGX, 15 well, Bio-Rad) for 30 minutes
at 200 V and then transferred them onto polyvinylidene difluoride membranes.
We first incubated each membrane with the primary antibody (1:1000 dilution)
and then with the fluorescent secondary antibody (anti-mouse DyLight 680 for
cTnI, PSer23/24 cTnI, and cMyBP-C; anti-rabbit 800 for phosphorylated cMyBPC, both antibodies from Cell Signaling Technologies) at a 1:7500 dilution. We
subsequently visualized all bands using a LI-COR Odyssey imaging system (LICOR Biosciences, Lincoln, NE) and analyzed the bands using Odyssey V3.0
image analysis software.
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We calculated the relative phosphorylation of the site by integrating the
densitometry profiles for the phosphorylated protein and total protein bands, and
normalizing to data for a single rabbit muscle sample (for phosphorylated and
total cTnI) or a non-failing sub-epicardial human sample (for phosphorylated and
total cMyBP-C) that was loaded on to every gel as a control.

2.5. Statistics
We analyzed the experimental data in SAS 9.1.3 (SAS Institute, Cary, NC) using
linear mixed effects models for A) the aging F344 rat study: incorporating 2 main
effects (age and transmural region) and their interaction and B) the human heart
failure study: incorporating 2 main effects (condition and transmural region) and
their interaction. Post-hoc analyses were performed using the Tukey-Kramer
method.
We used the mixed effect model because there was a fixed and a random effect
in the experimental designs. The animal ID/subject was a random effect while the
transmural region was a fixed effect (the 3 discrete regions-sub-epicardium, midmyocardium and sub-endocardium).
We assumed compound symmetry for the covariance structure because it is
assumed that every observation collected from an animal/subject (random effect)
was equally correlated with every other observation from the same subject.

34

Advantages of using the mixed effect model; for example in analyzing the
mechanical experiments for the human heart failure study was that it accounted
for an unbalanced design (6 non-failing and 10 failing hearts), allowed for
repeated measures (the 3 regions for each subject came from the same heart,
therefore the samples were spatially repeated) and the experiments were
hierarchically nested (2-3 preparations from the same region). Furthermore, the
linear mixed effects model method provided more statistical power than ANOVA
when multiple samples are analyzed from each heart.
Similar to a two –way ANOVA the interaction term in the linear mixed effect
model tells us if one main effect depends on the other. For example, if the
transmural regional pattern changes in the heart failure group when compared to
the transmural regional pattern in the non-failing group for a given response then
there is an interaction between the heart failure status and the transmural region.
We also analyzed the biochemical data for the aging F344 rat study and the
histology and biochemical data for the human heart failure study using the linear
mixed model data.
For the correlation plots, linear regression tests were performed in MATLAB
(Mathworks, Natick, MA). For all statistical analysis p values less than 0.05 were
considered significant. Data were reported as mean ± SEM.
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Table 2.2. Clinical characteristics.
A. Patients with heart failure
Sex

Age (y)

Cardiomyopathy

Medications

F

49

Non ischemic, idiopathic

Diuretic, Inotropes, Digoxin

M

65

Ischemic

Diuretic, ACE inhibitor/ARB, β-blockers,
Inotropes, Digoxin, Statin, Insulin
Diuretic, ACE inhibitor/ARB, β-blockers,
M

63

Ischemic
Statin

M

49

Non ischemic, idiopathic

Diuretics, Inotropes

M

39

Non ischemic, idiopathic

Inotropes, Statin

M

64

Ischemic

Diuretics, β-blockers, Inotropes, digoxin

M

61

Ischemic

Diuretic, ACE inhibitor/ARB, Inotropes,
Statin Diuretic, ACE inhibitor/ARB, β-blockers,
F

23

Non ischemic, postpartum
Inotropes

M

20

Non ischemic, idiopathic

Diuretic, ACE inhibitor/ARB, Digoxin

M

53

Ischemic

Diuretic, β-blockers, Inotropes, Digoxin

B. Donors with Non-failing hearts
Sex

Age (y)

Cause of death

F

31

Stroke

M

59

Stroke

F

18

Head Trauma

F

38

Stroke

M

28

Head Trauma

M

33

Head Trauma
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Figure 2.1. Transmural dissection of the left ventricle of a rodent
myocardium.
(A) Schematic (top) and images (bottom) of separation of transmural regions
from the LV free wall. After hearts were removed from the cannulae, the LV free
wall was dissected (left) and separated into three transmural regions: subepicardium (Epi), mid-myocardium (Mid), and sub-endocardium (Endo) of even
thickness (Figure 1A, adapted from Chung et al., 2013 64).
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Figure 2.2 External view of human hearts.
A) Non-failing and B) failing heart.

38

Figure 2.3. Chemically permeabilized multicellular preparation.
A frozen tissue sample from one region of the left ventricular heart was
mechanically disrupted and chemically permeabilized and one multicellular
preparation was tied between a force transducer and a motor.
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Figure 2.4. Experimental preparations.
A) Low and B) high magnification views of the central section of a representative
myocardial preparation immersed in a solution with a pCa value of 9.0.
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Figure 2. 5. Raw traces of the 3-stretch mechanical protocol with varying
Ca2+concentrations.
Representative A) force and B) length records for a multicellular preparation
immersed in solutions with different free Ca2+ concentrations. The short-range
force can be prominently observed as a non-linear force response to the first
stretch (4% of l0). The rate of tension recovery (ktr) is the rate at which tension
recovers after the shortening perturbation (20% of l0).
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Figure 2.6. Force-velocity raw traces and curves.
A) Superposed force and length records obtained during force-velocity
experiments performed with a representative preparation isolated from a
multicellular preparation B) Force-velocity (top) and Force-power (bottom) curves
for the same preparation. Colors show the corresponding data.
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Chapter 3. Decrease in cardiac troponin I phosphorylation contributes to
transmural pattern of myocyte relaxation that precede heart failure in aging
F344 rats

Aspects of this chapter were reported in the manuscript titled, “Altered ventricular
torsion and transmural patterns of myocyte relaxation precede heart failure in
aging F344 rats”. American Journal of Physiology: Heart and Circulatory
Physiology, September 2013, 305:H676-H686. PMID: 23792678
In this dissertation only the biochemical analysis and interpretation of the
biochemical results pertaining to the functional and computational analysis will be
discussed.

3.1. Introduction
The lifetime risk of developing heart failure is 20% for Americans ≥ 40 years of
age 11, 12, 89, 90. Epidemiological studies show that ~ 50% of patients with heart
failure have diastolic dysfunction and the prevalence of diastolic heart failure
increases with age 91. Patients with diastolic dysfunction have preserved ejection
fraction but their ventricles are unable to relax completely when filling with blood.
Due to which the heart cannot maintain cardiac output and this can lead to heart
failure (Figure 1.5).
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Age associated structural modifications like increased myocardial fibrosis 92 and
left ventricular remodeling 93 are thought to contribute to ventricular stiffness, a
hallmark of diastolic dysfunction 91, 94. However, growing evidence suggests
mechanisms more intrinsic to the myocyte. For example, our laboratory had
previously reported that increased myocardial stiffness in aging F344 rats (an
animal model of aging-associated heart failure 95, 96) are potentially due to
attached cross bridges during diastole (defined as short-range stiffness) 68.
Furthermore, the increase in ventricular stiffness correlated with the increased
proportion of β-MHC in aging 68. Other studies have reported modifications in
Ca2+ handling proteins and/or increase in expression of β-MHC to be involved in
prolonged myocyte contraction and relaxation in older F344 animals 97, 98.
Age-associated cardiovascular changes can be adaptive at first and potentially
beneficial but with progression of age they can become maladaptive and lead to
disease 7. Investigating the age-dependent modifications in myocyte function can
therefore reveal aberrant mechanisms that precede heart failure. Furthermore,
transmural cellular-level changes in the left ventricular wall with age could help
us identify region-specific changes that are beneficial in understanding
ventricular filling.
In this study, we examined F344 rodents at three ages: 6-, 18-, and 22-months.
To study the effects of normal aging we investigated the myocardial properties
between the 6- and 18-month old animals because F344 rats at these ages are
largely free of systemic disease 95, 96. To detect the adaptive limit of myocardial
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aging we studied the differences in myocardial properties between the 18- and
22-month old animals. We did not study animals beyond the 22-month time point
because by ~ 24-months of age F344 animals exhibit both systolic and diastolic
dysfunction 95, 96 and high rates of mortality 99. We investigated the transmural
changes that may occur in the sub-epicardium, mid-myocardium and subendocardium of the left ventricle because transmural heterogeneity in the
ventricular wall is thought to affect ventricular torsion 100, 101, a potential
prognostic tool to detect diastolic dysfunction.
We measured diastolic function and ventricular torsion using echocardiography.
Ca2+ transients and unloaded cell shortening properties (time constant of Ca2+
decay (τCa), time to peak (TP) of unloaded sarcomere shortening, time from peak
to 50% sarcomere re-lengthening (RT50)) were investigated using single
myocytes isolated from the 3 transmural regions (sub-epicardium, midmyocardium and sub-endocardium) of the left ventricles of the 6, 18- and 22month old F344 animals (Figure 3.1). Molecular mechanisms that would predict
slowed relaxation were simulated using computational modeling (Figure 3.3). As
mentioned previously in section 2.1.1, these results can be reviewed in further
detail in the published study 65. Here we will discuss the biochemical results that
pertain to the functional properties measured.

45

3.2. Results
We investigated the relative content and phosphorylation status of key
sarcomeric proteins that may contribute to the slowed relaxation with aging.
SERCA2a protein expression, assessed by Western blot and densitometry
analysis (methods-section 2.1.1) revealed that the sub-endocardial samples from
the 6-month old animals had significantly lower SERCA2a content than the subepicardial (p=0.039) and the mid-myocardial (p=0.032) samples (Figure 3.4).
Relative α- and β-MHC isoform expression was also measured in tissue
homogenates (methods-section 2.1.1). The relative content of α-MHC trended
downward with age, but the effect was not statistically significant (Figure 3.5).
We used Pro-Q Diamond staining to measure the relative total phosphorylation of
cTnI in our experimental samples (Figure 3.6). Post-hoc tests revealed that the
22-month old sub-epicardial samples were significantly less phosphorylated than
the mid-myocardial (p=0.037) and the sub-endocardial (p=0.016) samples of the
same age (Figure 3. 7). Similar tests were performed for other myofilament
proteins but we did not see any significant differences among the groups (Table
3.1, 3.2, and 3.3).

3.3. Discussion
In the spectrum of heart failure progression, many studies focus on the extremes
where the heart becomes maladaptive and heart failure is irreversible. If we can
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identify mechanisms that precede overt heart failure then we can potentially treat
it at an early stage. This study sought to identify transmural molecular level
modifications that underlie myocardial and cellular level functional changes that
occur in aging F344 rats.
Our data not only confirmed an age-dependent change in cardiac function seen
in prior studies 102 but also revealed a novel statistical age-region interaction with
slowed relaxation in the F344 myocytes (Figure 3.1 and 3.2 65). Specifically,
Figure 3.1 65 showed that the transmural regional pattern of relaxation properties
(τCa-p=0.02, TP-p<0.05, RT50-p<0.001) were similar between the 6- and the 18month old animals. However, this transmural pattern was disrupted in the 22month old animals and the sub-epicardial myocytes from the 22-month old
animals were affected the most (Figure 3.1 and 3.2 65).
We studied the relative content of SERCa2a, a major Ca2+ handling protein as it
could contribute to the alteration in τCa values (Figure 3.1 65). We found that there
was a heterogeneous expression of SERCa2a in the 6-month old animals where
both the sub-epicardial and mid-myocardial samples had significantly higher
SERCa2a content than the sub-endocardial samples (Figure 3.4). This result
qualitatively agreed with the increased τCa values (measure of Ca2+ decay) in
both the 6-month sub-epicardial and mid-myocardial myocytes (Figure 3.1 65).
This finding suggested that the increased expression of SERCa2a could
potentially lead to an increase in Ca2+ uptake and therefore slower Ca2+ transient
decay 103, 104. However, SERCa2a content did not seem to contribute to the
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reduced τCa values in the 18- and 22-month old animals. This suggested the
contribution of other mechanisms for example, phosphorylation of
phospholamban (regulates SERCA) has been previously shown to reduce with
age 105.
When τCa-RT50 relationship was assessed in the sub-epicardial, mid-myocardial
and sub-endocardial samples of all three age groups it was evident that the RT50
of the 22-month old sub-epicardial cells was highly sensitive to τCa (Figure 3.2.)
This meant that the slowed relaxation in the 22-month old sub-epicardial cells
could be due to modifications in contractile proteins. In order to identify the
molecular mechanisms simulations of unloaded sarcomere shortenings were
performed to predict τCa-RT50 relationship. It was evident that alteration in the
proportion of β-MHC isoform (which is known to modulate cross bridge
kinetics

68, 106)

did not change the relationship. However, the dissociation of Ca2+

from the troponin complex increased the slope of the τCa-RT50 relationship
(Figure 3.3).
We confirmed these predictions (Figure 3.3) by first investigating the relative
expression of MHC isoform. We saw a qualitative decrease in the proportion of
α -MHC isoform with age, similar to previous studies 68, 97 but we did not find any
significant differences within groups (Figure 3.5).
The effect of dissociation of Ca2+ from the troponin complex could not be tested
directly but a previous study suggested that the decrease in phosphorylation of
cTnI slows cardiac relaxation by reducing the rate at which Ca2+ unbinds from the
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troponin complex 107. Therefore, we analyzed relative cTnI phosphorylation in the
F344 animals. A significant decrease in phosphorylation of cTnI was found in the
sub-epicardial samples when compared to the mid-myocardial and subendocardial samples of the 22-month old animals (Figure 3.6 and 3.7). This
biochemical result confirmed the computational prediction (Figure 3.3). Previous
studies also support our results because cTnI phosphorylation has been shown
to decrease with heart failure 108, 109 and can affect myocyte kinetics 107, 110 and
Ca2+ sensitivity 108, 109.

3.3.1. Conclusion
In this study, the decrease in phosphorylation of cTnI seems to be an important
modulator of myocyte relaxation in a region-specific manner of the aging F344 rat
myocardium. Specifically, the reduced cTnI phosphorylation in the sub-epicardial
cells contributes to the slowed relaxation observed in 22-month old subepicardial cells. Both of these molecular and cellular level alterations in the subepicardial cells may contribute to the reduction in ventricular torsion observed in
these animals at 22-months 65. Together these results suggest that regionspecific changes in the left ventricular wall may precede heart failure and lead to
diastolic dysfunction in aging F344 rats.
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Table 3.1. Content of selected sarcomeric proteins.
Myosin

Actin

cTnT

cTnI

Epi

0.71±0.16

0.66±0.18

0.24±0.24

0.93±0.08

Mid

0.70±0.09

0.82±0.25

0.47±0.09

0.68±0.08

Endo

0.68±0.07

0.50±0.07‡

0.48±0.27

0.58±0.05

Epi

0.70±0.12

0.58±0.13

0.29±0.04

0.49±0.08

Mid

0.60±0.05

0.58±0.08

0.25±0.08

0.62±0.09

Endo

0.47±0.07

0.68±0.12

0.60±0.35

0.78±0.25

Epi

0.54±0.09

0.81±0.24

0.43±0.14

0.70±0.18

Mid

0.89±0.23

0.66±0.15

0.52±0.15

0.93±0.35

Endo

0.57±0.05

0.41±0.03§

0.28±0.03

0.81±0.09

Main statistical

Age

0.676

0.967

0.965

0.617

effects and

Region

0.174

0.147

0.928

0.942

Age *Region

0.223

0.132

0.165

0.259

6-month old

18-month old

22-month old

interaction
(p values)
Protein contents are expressed in arbitrary units and were calculated by normalizing to data
obtained for each protein from a 6-month old sub-epicardial sample that was loaded onto
every gel as a control. Different from the sub-epicardial region of the same condition: §
p<0.05. Different from the mid-myocardial region of the same condition: ‡ p<0.05.
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Table 3.2. Content of selected sarcomeric proteins.
Tropomyosin

MLC-2

MLC-1

Epi

0.51±0.25

0.49±0.27

0.76±0.22

Mid

0.53±0.18

0.49±0.15

0.74±0.12

Endo

0.41±0.08

0.17±0.02

0.68±0.08

Epi

0.29±0.04

0.15±0.01

0.48±0.03

Mid

0.46±0.10

0.31±0.12

0.56±0.21

Endo

0.46±0.10

0.36±0.04

0.61±0.12

Epi

0.35±0.13

0.34±0.15

0.43±0.18

Mid

0.43±0.10

0.57±0.28

0.72±0.33

Endo

0.32±0.04

0.19±0.05

0.70±0.11

Main statistical

Age

0.770

0.763

0.658

effects and

Region

0.363

0.160

0.565

Age *Region

0.567

0.285

0.764

6-month old

18-month old

22-month old

interaction
(p values)
Protein contents are expressed in arbitrary units and were calculated by
normalizing to data obtained for each protein from a 6-month old sub-epicardial
sample that was loaded onto every gel as a control.
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Table 3.3. Phosphorylation of selected sarcomeric proteins.
Phospho

Phospho

Phospho

cTnT

Tropomyosin

MLC-2

Epi

1.11±0.26

1.87±0.56

1.46±0.30

Mid

0.95±0.31

1.32±0.132

2.09±0.35

Endo

1.90±0.62

1.69±0.21

2.11±0.38

Epi

0.85±0.41

2.05±0.27

2.79±0.73

Mid

1.50±0.81

1.57±0.27

2.07±0.12

Endo

1.25±0.72

1.34±0.32

1.55±0.17

Epi

0.87±0.40

2.98±1.66

1.79±0.75

Mid

1.22 ±0.26

2.20±0.38

1.27±0.18

Endo

1.80±0.24

2.24±0.17

2.17±0.64

Main statistical

Age

0.965

0.364

0.433

effects and

Region

0.165

0.368

0.885

Age *Region

0.689

0.971

0.313

6-month old

18-month old

22-month old

interaction
(p values)
Phosphorylation levels are expressed in arbitrary units and were calculated by
normalizing to data obtained for each protein from a 6-month old sub-epicardial
sample that was loaded onto every gel as a control.
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Figure 3.1. Transmural patterns of Ca2+ handling and contraction dynamics
are altered with age.
A) Mean values (±SEM) of the time constant of F340/380 decay after peak (τCa) for
each age-region group. (B, C) Same as panel A but showing time-to-peak (TP)
unloaded sarcomere shortening and time from peak to 50% sarcomere relengthening (RT50). * p < 0.05 vs. cells from the same region at 6 months of age.
† p < 0.05 vs. endocardial cells at the same age. ‡ p < 0.05 vs. midmyocardial
cells at the same age.
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Figure 3.2. Aging alters Ca2+-relaxation coupling in epicardial myocytes.
Plotted points show RT50 vs. τCa for each cell in the study, grouped according to
region and animal age. Analysis of covariance on τCa-RT50 relations indicates
that the slope depends significantly on the age-region group (p < 0.001). RT50 in
epicardial myocytes from 6-month-old rats was significantly less sensitive to τCa
than in 18- and 22-month-old cells from the same region.
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Figure 3.3. Computer simulations of unloaded sarcomere shortening.
Ca2+ transients with various rates of decay (τCa) were used as inputs to predict
relationships between τCa and RT50 (time from peak shortening to 50% relengthening) under different conditions. A) Example input Ca2+ transients of
increasing τCa and corresponding SL outputs for the baseline model (40% βMHC, TnC Ca2+ affinity 0.3 μmol L-1). B) Sensitivity of the τCa-RT50 relation to
doubling and halving relative β-MHC content. C) Sensitivity of the τCa-RT50
relation to a 20% increase in TnC Ca2+ affinity.
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Figure 3.4. Expression of SERCa2a.
A) Representative immunoblots showing SERCa2a expression in F344 rats. B)
Symbols show the mean SERCa2a measured for each region for each heart.
A.U. stands for arbitrary units. In this figure, and in all similar panels, thin lines
join data points from the same heart. Thick bars show the mean data for the
region. The text above the plot shows p values for the main statistical effects.
Significant differences between regions, tested separately for the three ages, are
listed in the inset box. Significant differences due to aging, tested separately for
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each region, are indicated by asterisks (* indicates p<0.05, ** indicates p<0.01,
*** indicates p<0.001).
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Figure 3.5. Shift in MHC isoform.
A) Representative bands from mid-myocardial samples of various ages showing
separated α- and β-MHC isoforms and B) the mean α-MHC isoform percentages
across groups.
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Figure 3.6. Broadrange gel stained for phosphorylated and total sarcomeric
proteins.
Two images of a single representative gel stained with Pro-Q Diamond (left) and
SYPRO Ruby (right). The Pro-Q Diamond stain is more sensitive to
phosphoproteins while SYPRO Ruby indicates total protein content.
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Figure 3.7. Decreased cTnI phosphorylation in 22 month old sub-epicardial
samples.
A) Symbols show the mean Phospho cTnI measured for each region for each
heart using Pro-Q Diamond (phospho-sensitive stain). A.U. stands for arbitrary
units.

Copyright © Premi Haynes 2014
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Chapter 4. Transmural heterogeneity of cellular level contractile function in
human heart failure

Aspects of this chapter will be reported in the manuscript titled, “Transmural
heterogeneity of cellular level power output is reduced in human heart failure”.
Journal of Molecular and Cellular Cardiology, accepted.
DOI:10.1016/j.yjmcc.2014.02.008

4.1. Introduction
Clinical studies have shown that transmural variation in the contractile function of
human myocardium may influence clinical end-points 26, 28. For example, a study
by Wachtell et al. 26 followed 840 patients for 3,914 patient-years and showed
that shortening of the middle transmural region of the left ventricular free wall is a
better predictor of cardiovascular death, myocardial infarction, and stroke, than
the shortening of other regions, or ejection fraction. However, the mechanisms
that underlie these results, which may include transmural variation in cellular and
molecular properties, are not well understood.
Previous studies using human hearts have demonstrated that action potentials
and Ca2+ transients vary systematically across the left ventricular free well, and
that these effects probably reflect transmural-region specific expression of ion
channels and ionic transporters 43, 44. There are a few reports in the animal-based
literature showing that tissue samples from different parts of the ventricular wall
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(specifically the sub-epicardial, mid-myocardial, and sub-endocardial regions)
express different sarcomeric proteins and exhibit variable contractile
properties

97, 100, 101, 111.

Less is currently known about potential transmural

variation in contractile function. Therefore, the goals of our study was to test the
hypotheses that human hearts exhibit transmural heterogeneity of cellular level
contractile properties, and that heart failure produces region-specific changes in
contractile function. In order to evaluate both the active and passive mechanical
properties of the tissue samples, we performed experiments using multicellular
chemically permeabilized preparations.
The results showed that cellular level indices of systolic function (power output
and isometric force) exhibit transmural heterogeneity in non-failing human hearts.
Specifically, samples from the mid-myocardium developed more power and more
force than samples from the sub-epicardial and sub-endocardial regions. Heart
failure reduced power and force by ~20% but affected mid-myocardial samples
more than tissue from the other regions. As a result, failing hearts exhibited less
transmural heterogeneity. Additional data from histological and biochemical
assays suggested that these contractile changes reflect a region-specific
increase in fibrosis and modifications to the content and phosphorylation status
of sarcomeric proteins including cTnI, desmin and MLC-1.
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4.2. Results

4.2.1. Power output
We measured maximum power output, an in vitro index of systolic function, using
multicellular permeabilized preparations (Figure 2.4 and 4.1). Figure 4.2A shows
force-velocity and force-power curves that we measured using preparations
obtained from the sub-epicardial, mid-myocardial and sub-endocardial regions of
one non-failing and one failing heart. In the non-failing samples, peak power
output was higher for the mid-myocardial sample than it was for the subepicardial and sub-endocardial samples (lower left panel). The failing samples
exhibited less transmural variation (lower right panel).
Figure 4.2B shows collated data for the 6 non-failing and 10 failing hearts. We
found a significant interaction (p=0.030) between region and heart failure
condition, which implies that the heart failure status affects the sub-epicardial,
mid-myocardial, and sub-endocardial regions in different ways. Maximum power
output was significantly lower (p=0.009) for the heart failure samples
(0.37 ± 0.02 µW mg -1) than for the non-failing samples (0.50 ± 0.03 µW mg -1).
The post-hoc tests revealed that in the non-failing samples, the maximum power
output of the mid-myocardial preparations (0.59 ± 0.06 µW mg -1) was greater
than that of the sub-epicardial (0.46 ± 0.03 µW mg -1, p value=0.021) and the
sub-endocardial preparations (0.46 ± 0.04 µW mg -1, p value=0.015). We
observed no significant transmural differences in the heart failure samples. Heart
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failure thus lowered the power output of mid-myocardial samples more than it
lowered the power output of sub-epicardial and sub-endocardial preparations.

4.2.2. Isometric force
Figure 4.3A shows that the isometric force also exhibited transmural variation in
non-failing hearts and that the transmural pattern of variation was altered by
heart failure (p<0.001). Since power is the product of force and velocity, these
data suggest that the transmural variation in power output primarily reflects
changes in force-generating capacity rather than changes in shortening velocity
(which did not exhibit significant differences, Figure 4.3B). Heart failure lowered
isometric force values normalized to cross-sectional area from
12.27 ± 0.61 kN m-2 to 9.78 ± 0.37 kN m2 (p=0.042). Post-hoc analysis showed
that the non-failing samples exhibited transmural heterogeneity. Specifically, the
maximum force generated by samples from the mid-myocardium
(14.3 ± 1.33 kN m2) was higher than the force generated by the sub-epicardial
(10.96 ± 0.74 kN m-2, p=0.008) and the sub-endocardial (11.47 ± 0.86 kN m-2,
p=0.026) preparations. In these experiments, the samples from the failing hearts
also exhibited heterogeneity, with the mid-myocardial preparations generating
the least amount of force (8.80 ± 0.09 kN m-2). Heart failure thus lowered the
force generating capacity of the mid-myocardial preparations more than that of
the sub-epicardial and sub-endocardial samples.

64

4.2.3. Calcium sensitivity
Figure 4.4A shows normalized isometric tension plotted as a function of the
activating Ca2+ concentration (where pCa = -log10[Ca2+]) for preparations from the
three transmural regions of non-failing (left panel) and failing (right panel) hearts.
In the non-failing samples, Ca2+ sensitivity (assessed as the Ca2+ concentration
required to produce half the maximum force) was 0.075 pCa units greater in the
sub-endocardial samples than in the sub-epicardial samples (p=0.010, Figure
4.4B). No transmural differences were observed in the failing samples. The
progressive transmural change in calcium sensitivity that occurs in non-failing
hearts is thus disrupted by heart failure (interaction term, p=0.047).

4.2.4. Short-range components
Figure 4.5A shows that the short-range stiffness exhibited transmural variation in
non-failing hearts and that the transmural pattern of variation was altered by
heart failure (p<0.001). Post-hoc analysis showed that the non-failing samples
exhibited transmural heterogeneity. Specifically, short-range stiffness of samples
from the mid-myocardium was higher than short-range stiffness of samples from
the sub-epicardium (p=0.026). Samples from the failing hearts also exhibited
transmural heterogeneity. The mid-myocardial samples were the least stiff and
significantly different than the sub-epicardial samples (p=0.016). We did not find
significant interaction between region and heart failure status for relative shortrange force (p=0.475, Figure 4.5B). These results suggest that heart failure
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lowered the short-range stiffness in the mid-myocardial preparations more than
the sub-epicardial and sub-endocardial samples suggesting a decrease in
myocardial stiffness due attached cross bridges.

4.2.5. Rate of tension redevelopment
The rate of tension redevelopment was plotted as a function of relative tension
for both the non-failing and failing samples from different transmural regions
(Figure 4.6). We did not find any significant difference in the rate of tension
redevelopment (ktr) at high Ca2+ concentration (pCa 4.5) with heart failure status
or region (Figure 4. 7A). However, we found that there was a region dependence
(p=0.008) in ktr at submaximal level of Ca2+ (pCa 5.7). Furthermore, the subendocardial samples of failing hearts had significantly slower ktr than the subepicardial (p=0.009) and the mid-myocardial (p=0.001) samples of the failing
hearts (Figure 4. 7 B).

4.2.6. Collagen content
Figure 4.8 shows representative images of myocardial sections that had been
stained with picrosirius red. Quantification showed that there was a significant
interaction (p=0.020), which implied that heart failure affected the regions
differentially. Heart failure also increased the proportion of tissue that was
collagen from 0.103 ± 0.007 to 0.219 ± 0.012 (p=0.021, Figure 4.9A). Unlike the
non-failing samples (which were not transmurally heterogeneous), the sections
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cut from the three transmural regions of failing tissue all had collagen contents
that were significantly different from each other (p values for all post-hoc tests <
0.05). In the failing samples, the collagen to tissue ratio in the mid-myocardial
sections was greater than that in the sub-epicardial and sub-endocardial sections
by ~0.117 and ~0.041 respectively.
The collagen to tissue ratio in the stained sections was negatively correlated with
the relative contents of actin (Figure 4.9B) and myosin (Figure 4.9C) in wet tissue
samples from the same biospecimens. This is consistent with a mechanism in
which myocytes are replaced by extracellular matrix proteins when fibrosis
develops.

4.2.7. Modifications in sarcomeric proteins
We investigated the potential changes in the isoform content and
posttranslational status of sarcomeric proteins using gel electrophoresis and
western blotting (see methods-section 2.4). The key findings were that heart
failure status decreased the relative content of cTnI (p=0.021, Figure 4.10 and
4.11A), reduced relative phosphorylation of cTnI at Ser23/24 (p=0.012) in the
failing samples (Figure 4.12), increased the content of desmin protein (p<0.001,
Figure 4.10 and 4.13A), reduced desmin’s relative level of phosphorylation
(p=0.006, Figure 4.10 and 4.13B), and increased the relative content of N2BA
isoform of titin (p=0.047, Figures 4.14).
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No other statistically significant effects of heart failure status and/or transmural
region were revealed by the linear mixed model analyses (Tables 4.1, 4.2, 4.3,
4.4 and 4.5).

4.2.7.1. Cardiac troponin I
Cardiac troponin I (cTnI) content was reduced by 23% in samples from heart
failure patients (p=0.021, Figure 4.10 and 4.11A). There was a region dependent
difference in phosphorylation of cTnI (p=0.041). Post-hoc analysis showed that
the sub-epicardial region was more phosphorylated than the sub-endocardial
region of the heart failure group (p=0.004). The relative phosphorylation of cTnI
at Ser23/24 was also reduced (p=0.012) in the failing samples (Figure 4.12).

4.2.7.2. Desmin
Heart failure increased the content of desmin protein (p<0.001, Figure 4.10 and
4.13A) but reduced its relative level of phosphorylation (p=0.006, Figure 4.10 and
4.13B).

4.2.7.3. Cardiac myosin binding protein-C
There was no significant difference in total phosphorylation of cMybp-c and its
content (Tables 4.1 and 4.4). However, western blotting with a site-specific
antibody showed that the phosphorylation of cMyBP-C at Ser302 depended on
68

transmural region (p=0.014, Figure 4.15). In non-failing hearts, this residue was
also more phosphorylated in samples from the sub-epicardial region than in
tissue from the mid-myocardium (p=0.047, Figure 4.15B).

4.2.7.4. Titin
Titin isoform content was also altered by heart failure. The relative amount of this
protein expressed as the larger N2BA isoform increased from 0.541 ± 0.028 in
the non-failing samples to 0.653 ± 0.022 in the samples from failing hearts
(p=0.047, Figure 4.14A and B). Sub-endocardial preparations from failing hearts
also exhibited higher levels of N2BA phosphorylation than sub-epicardial
(p=0.006) and mid-myocardial (p=0.037) preparations (Figure 4.14C).

4.2.8. Molecular mechanisms influencing contractile function
Most of the functional parameters we measured in this work exhibited large
within-group variability. For example, the power output of mid-myocardial
preparations from non-failing hearts ranged from 0.443 to 0.747 µW mg-1, a span
of 51%. We therefore used linear regression tests to test whether changes in the
content and posttranslational status of sarcomeric proteins could explain the
variance of the functional measures. This analysis revealed 24 relationships with
p values less than 0.05. These relationships are shown in Tables 4.6 and 4.7 and
Figures 4.16 and 4.17.
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4.2.8.1. Power output
Figure 4.16A shows that power increased with the relative content of cTnI
(p=0.042). Figure 4.16B and C show that power decreased with the relative
content of desmin (p=0.041) but increased with its relative phosphorylation
(p=0.046). Finally, Figure 4.16D and E show that power increased with the
relative content of MLC-1 (p=0.034) but decreased with the molecule’s relative
phosphorylation (p=0.006).

4.2.8.2. Rate of tension redevelopment
At maximal Ca2+ activation ktr was significantly correlated with thick filament
associated proteins. Figure 4.17A and B show that ktr increased with cMyBP-C
(p=0.002) and decreased with its phosphorylation (p=0.031). Figure 4. 17C and
D show that ktr increased with MLC-1 content (p<0.001) and its phosphorylation
(p=0.013) and Figure 4.17E shows that ktr increased with MLC-2 (p=0.001).
Other significant correlations between ktr and other sarcomeric protein are listed
in Table 4.6.

4.2.8.3. Other functional-biochemical relationships
Table 4.7 shows that force (p=0.045) increased with the relative content of cTnI.
Resting tension was positively correlated with the relative phosphorylation of cTnI
at Ser23/24 (p=0.006) which suggests that this residue may influence the
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mechanical properties of titin and/or the regulation of binding sites for myosin on
the actin filament. The relative phosphorylation of cMyBP-C at Ser282 (p=0.001)
and at Ser273 (p=0.023) predicted the maximum shortening velocity of the
preparations. These posttranslational modifications are mediated primarily by
PKA 112 and this kinase is known to increase the maximum shortening velocity of
rat myocardium 113. However, the specific relationships between the
phosphorylations of Ser282 and Ser273 and shortening velocity are new findings.

4.3. Discussion
Clinicians already recognize the significance of transmural variation in contractile
function. For example, imaging studies have shown that shortening of the middle
transmural region is a better predictor of cardiovascular death than traditional
measures of global ventricular function such as ejection fraction 26, 28. The
American Society of Echocardiography also notes in its guidelines that
“Contraction of muscle fibers in the LV midwall may better reflect intrinsic
contractility than contraction of fibers at the endocardium” 114. Our current work
reveals four new cellular and molecular level results that may help to explain
these clinically-relevant observations 26, 28.
First, non-failing human hearts exhibit transmural heterogeneity of contractile
properties (Figures 4.2- 4.4). Second, heart failure depresses power and force
and has its biggest negative impact on mid-myocardial tissue. Failing hearts thus
exhibit less transmural heterogeneity in cellular level contraction than non-failing
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hearts (Figures 4.2 and 4.3). Third, human heart failure produces more fibrosis in
mid-myocardial tissue than it does in sub-epicardial and sub-endocardial
samples (Figure 4.9). This may explain why heart failure produces the greatest
contractile deficits in the mid-myocardium as the additional connective tissue is
likely to displace functioning myocytes. Fourth, power and rate of tension
redevelopment correlate with the relative content and relative phosphorylation of
key sarcomeric proteins (Figure 4.16 and 4.17 and Table 4.7). Therefore,
therapies targeting these proteins may be particularly effective treatments for
human heart failure.

4.3.1. Region-specific modifications in systolic function
During systole, the heart contracts against its afterload to eject blood from the
ventricle. This can be mimicked in vitro by allowing permeabilized myocardial
preparations to shorten against a controlled force 115 (Figure 4.1). The power
output for each load is calculated by multiplying the force that the muscle
generates by its shortening velocity. Figure 4.2 shows that the maximum power
output exhibited significant transmural variation in non-failing hearts and was
reduced by ~25% in failing organs (p=0.009). Further analysis suggests that
these effects primarily reflect altered force generation (Figure 4.3A) since
maximum shortening velocity was not influenced by heart failure status or
transmural region (Figure 4.3B).
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No previous studies have used human samples to assess transmural variation in
power output. However, a few studies have measured the effect of heart failure
on isometric force generation, with potentially conflicting results. For example,
separate studies using epicardial biopsies 116 and samples from unspecified
regions of the heart 117 have shown that isometric force is reduced by ~80% in
patients with heart failure. Other works, using samples from unspecified regions
of the left ventricle, suggests that there is no significant effect of heart failure on
maximum isometric force 118-120. In the present experiments, heart failure reduced
the average force generated by the experimental preparations (Figure 4.3A,
p=0.042). However, post-hoc analysis of the different transmural regions showed
that the effect was only significant for the mid-myocardial samples (p<0.001) and
that heart failure did not significantly reduce the force generated by the subepicardial (p=0.935) or the sub-endocardial (p=0.120) preparations. These
results imply that heart failure influences force generation in a transmural specific
manner in humans. Researchers developing future studies in this area may
therefore wish to consider including transmural region as an independent
grouping factor when they design their experiments.

4.3.2. Failing hearts have increased mid-myocardial fibrosis
Increased fibrosis was an important factor in these experiments. Figure 4.9A
show that heart failure increased the relative content of collagen in the
myocardial sections, and that the mid-myocardial samples of the failing hearts
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contained more collagen than the matching sub-epicardial (p<0.001) and subendocardial (p=0.043) sections. Increased collagen was also associated with
lower relative contents of actin and myosin (Figure 4.9B-C). Additional analyses
showed that force (p=0.325, Figure 4.18A) and maximum power p=0.012, Figure
4.18B) were correlated with actin content. Together these data support the
hypothesis that in human heart failure, increased fibrosis depresses contractile
function by replacing myocytes with extracellular matrix proteins.
The increased fibrosis might have been expected to raise passive force in the
samples from the failing hearts. However, linear mixed model analyses showed
that neither passive force (Figure 4.19A) nor passive stiffness (Figure 4.19B) at a
sarcomere length of 2.2 µm were influenced by heart failure status or transmural
region (all main statistical effects > 0.05). This probably reflects a compensatory
effect of titin isoform expression. Consistent with previous studies 121, 122,
samples from failing hearts had a greater relative content of the large N2BA
isoform of titin (p=0.047, Figure 4.14B). This isoform shift tends to decrease
passive stiffness and seems to counteract the mechanical effect of increased
fibrosis in the samples from the failing hearts.
Titin phosphorylation has also been shown to change passive stiffness 123.
Although phosphorylation of N2BA isoform of titin did not change with heart
failure (condition p=0.825, Figure 4.14C), the experimental data revealed a novel
transmural heterogeneity. Sub-endocardial samples from failing hearts had
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greater levels of phosphorylation than samples from the other regions (p=0.037
versus mid-myocardium, p=0.006 versus sub-epicardium, Figure 4.14C).
Another aspect of myocardial stiffness comes from the cross bridges that remain
attached to the actin filaments during diastole. In this study short-range stiffness
was significantly lower in heart failure (Figure 4.5A). The combined functional
data of passive stiffness and short-range stiffness suggests that the failing
myocardial samples may not be stiff. This is possible because most of the failing
hearts in this study were dilated and dilated ventricles are thought to be
compliant 124.

4.3.3. Region-specific Modification in Ca2+ sensitivity
In vivo function may be particularly sensitive to changes in Ca2+ sensitivity
(defined as the free Ca2+ concentration required to generate half-maximum force)
since myocytes are not maximally activated during a normal heartbeat. According
to a Chapter 3, transmural variation in Ca2+ sensitivity may also modulate
ventricular torsion 65. In the present experiments (Figure 4.4) non-failing samples
exhibited a statistically significant increase in Ca2+ sensitivity (p=0.010,
ΔpCa50=0.075) going from the sub-epicardial to the sub-endocardial
preparations. However, samples from failing hearts did not show a significant
transmural trend.
Two previous studies using human myocytes isolated from unspecified
ventricular locations have shown that Ca2+ sensitivity increases with heart failure
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108, 125.

Another study 117 documents no change. Again, similar to the previous

discussion relating to isometric force generation, it is difficult to interpret these
data without more information about the transmural source of the sample 108, 117,
125.

Two additional projects have used animal tissues to assess potential transmural
changes in Ca2+ sensitivity in pigs 47 and rats 46. Both studies showed that Ca2+
sensitivity increased from the epicardium to the endocardium in healthy hearts,
similar to the present work. The rodent study also showed that transmural
variation in Ca2+ sensitivity was eliminated 46 14 weeks after a myocardial
infarction which is, again, broadly consistent with the current data from failing
hearts (Figure 4.4).
Modulation of Ca2+ sensitivity is complex. The current data suggest that one
molecular mechanism that may modulate the transmural variation in pCa50 in
non-failing hearts (Figure 4.4) is phosphorylation of cMyBP-C. Post-hoc tests
showed that Ser302 phosphorylation in non-failing epicardial samples was
greater than in non-failing mid-myocardial tissue (p=0.047, Figure 4.15A-B)
Regression analysis showed that pCa50 values for the non-failing preparations
were negatively correlated with both total cMyBP-C phosphorylation (p=0.002,
Figure 4.20A) and Ser302 phosphorylation (p=0.045, Figure 4.20B). The former
finding reinforces data from a previous study using myocardial samples from
unspecified regions of human hearts 120 but the new link between
phosphorylation of cMyBP-C at Ser302 and pCa50 is a novel finding.
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Other groups have shown that cTnI phosphorylation can also influence Ca2+
sensitivity 118, 126. In this study, site-specific cTnI phosphorylation was reduced in
heart failure samples at Ser23/24 (Figure 4.12B, p=0.012) but there was not a
significant relationship between this parameter and pCa50 (r=0.034, p=0.850,
data not shown). Total cTnI phosphorylation was not correlated with pCa50 either
(r=-0.011, p=0.942, data not shown). However, site-specific phosphorylation of
cTnI at Ser 23/24 correlated with cMyBP-C (Figure 4.21). cTnI undergoes many
complex posttranslational modifications – the human cardiac isoform has 14
phosphorylation sites 127. It is therefore possible that more detailed analysis
might have revealed significant relationships. For example, phosphorylation of
cTnI at Ser149 has been shown to increase Ca2+ sensitivity 128 but this
modification was not investigated in this study.
Another posttranslational modification that has been linked to changes in
myocardial Ca2+ sensitivity is phosphorylation of MLC-2. Davis et al. 100 have
reported that MLC-2 phosphorylation is greater in sub-epicardial than in subendocardial tissue. Data from rat trabeculae 129 suggest that this phosphorylation
gradient would increase Ca2+ sensitivity in epicardial tissue. However, the
situation is complex, because van der Velden et al. 109 have shown that
increased phosphorylation of MLC-2 decreases pCa50 values. Unfortunately,
MLC-2 phosphorylation was not studied in this work.
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4.3.4. Proteins that influence power output
The transmural heterogeneity of myocardial power output and its modification by
heart failure are the key findings of this study. However, it was not possible to
identify a specific sarcomeric protein that explains the functional changes.
The content of intact cTnI (Figure 4.11A) was reduced in biospecimens from
failing hearts (p=0.021) but did not exhibit transmural variation (interaction term,
p=0.853). Further analysis of these data showed that cTnI content was lower in
patients with ischemic heart failure than in patients with non ischemic disease
(p=0.029, Figure 4.22). This is consistent with a study by McDonough et al. which
showed that cTnI is degraded in human hearts after ischemic injury 130.
Degradation of cTnI inhibits contractility in mice 131 and the current data show
that this mechanism probably impacts human myocardial function too. Power
output (Figure 4.16A) and force (Table 4.7) both correlated with the relative cTnI
content, indicating that proteolyis of cTnI may be another impact factor in human
disease 131.
Desmin, a structural protein that links myofibrils at Z-disks and maybe involved in
force transmission 132, has been proposed as a potential biomarker for heart
failure 133, 134. Pawlak et al. 134 had previously shown that desmin content is
increased in endocardial biopsies from patients with heart failure and this result
was confirmed in the present work (Figure 4.13A). There was also a decrease in
the total phosphorylation of desmin in samples from failing hearts (Figure 4.13B)
135.

Although desmin content did not vary with transmural region (p=0.514), the
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regression tests summarized in Figure 4.16B-C show that changes to the content
and phosphorylation of this protein may modulate power output.
Similarly, power increased linearly with MLC-1 content (p=0.034, Figure 4.16D)
and decreased with MLC-1’s relative phosphorylation (p=0.006, Figure 4.16E).
Since MLC-1 binds to the lever arm of the myosin head near the convertor
domain, it is ideally positioned to influence force generation and/or kinetics. For
example, previous work by Morano et al. 136 and new data in Table S7 show that
MLC-1 phosphorylation decreases Vmax. There are only a few studies describing
MLC-1 phosphorylation but phosphorylation sites corresponding to the human
isoform are known as Thr64 and Ser194/195 137. Intriguingly, phosphorylation of
MLC-1 has recently been shown to increase the molecule’s degradation by
matrix metalloproteinase-2 138-140. When combined with these previous findings,
the new data presented in this manuscript show that MLC-1 modulates power
output in human myocardium, and that loss of MLC-1 (perhaps following its
phosphorylation) decreases contractility. To our knowledge, this is the first study
to identify significant correlations between the power output of human
myocardium and modifications to the content and phosphorylation status of cTnI,
desmin and MLC-1.
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4.3.5. Proteins that influence rate of tension redevelopment
The rate at which the myosin cross bridges generate force is an in vitro measure
of the rate at which the ventricles generate pressure during systole. This property
did not change significantly with heart failure status in our study (Figure 4.7).
In animal models of cardiac disease and aging ktr has been shown to modulate
with a shift in the isoform content of MHC. For example, F344 rats express more
β-MHC with age 15 and this shift in the relative content of MHC isoform has been
shown to significantly correlate with slowed ktr 68, 106, 141. In humans a shift in
MHC isoform content in less likely to modulate ktr because ~95% of MHC
expressed in the left ventricles is β-MHC and does not change much with heart
failure 142. In our study the relative expression of α and β-MHC content was
unaffected by heart failure. None of the ventricular samples contained detectable
amounts of the α isoform although paired α and β myosin heavy chain bands
were clearly resolved in atrial samples used as positive controls (Figure 4.23).
These results suggested that there are other proteins that modulate ktr in human
myocardium. In our study we found cMyBP-C, MLC-2 and MLC-1, three proteins
that were structurally bound to MHC to be significantly correlated with ktr (4.17).
Previous studies have shown that ktr increases significantly in cMyBP-C knockout
mice 143, 144 and by phosphorylation of cMyBP-C through PKA incubation at
submaximal concentration of calcium 145. Both of these findings suggest that the
relative content and phosphorylation of cMyBP-C can modulate ktr, similar to our
study (Figure 4.17A and B).
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Similarly MLC-1 and MLC-2 both are located on the lever arm of the myosin head
and are known to affect cross bridge kinetics 146-148. In our study ktr increased
significantly with the contents of both these proteins (Figure 4.17C and E).
Another important result was that cMyBP-C was highly correlated with MLC-1
and MLC-2 content (p<0.001, Figure 4.24), which suggested that the effect of
each of these thick filament protein may be masked by the other (called
multicolinearity in statistical terms). Therefore an animal model maybe useful to
investigate the effect of each of these proteins on ktr.

4.3.6. Conclusion
This is the first study to show that (1) the contractile properties of non-failing
human hearts exhibit transmural variation, and that (2) heart failure alters the
transmural pattern as well as depressing overall function.
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Table 4.1. Content of selected sarcomeric proteins in non-failing and failing
tissue
cMyBP-C

cTnT

Actinin

Epi

1.17±0.18

1.63±0.47

1.07±0.17

Mid

1.03±0.10

1.21±0.31

0.94±0.09

Endo

1.11±0.10

1.25±0.37

0.92±0.07

Epi

1.03±0.07

1.10±0.29

1.06±0.07

Mid

1.09±0.07

1.20±0.31

1.14±0.10

Endo

0.88±0.10

1.01±0.34

0.99±0.30

Main statistical

Condition

0.388

0.616

0.439

effects and

Region

0.448

0.655

0.452

Condition *Region

0.231

0.455

0.537

Non-failing

Heart failure

interaction
(p values)
Protein contents are expressed in arbitrary units and were calculated by
normalizing to data obtained for each protein from a non-failing subepicardial sample that was loaded onto every gel as a control.
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Table 4.2. Content of myosin light chain proteins in non-failing and failing
tissue.
MLC-1

MLC-2

Epi

1.24±0.14

1.22±0.22

Mid

1.09±0.08

1.11±0.10

Endo

1.16±0.11

1.22±0.22

Epi

1.12±0.10

1.15±0.11

Mid

1.18±0.09

1.15±0.10

Endo

0.95±0.14

1.01±0.15

Main statistical

Condition

0.589

0.702

effects and

Region

0.395

0.725

Condition *Region

0.243

0.639

Non-failing

Heart failure

interaction
(p values)
Protein contents are expressed in arbitrary units and were
calculated by normalizing to data obtained for each protein from a
non-failing sub-epicardial sample that was loaded onto every gel
as a control.
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Table 4.3. Content of Myosin Heavy Chain (MHC) and Actin in non-failing and
failing tissue.
MHC

Actin

Epi

0.79±0.08

0.71±0.10

Mid

0.71±0.05

0.71±0.04

Endo

0.78±0.06

0.71±0.04

Epi

0.74±0.03

0.66±0.02

Mid

0.69±0.04

0.58±0.03

Endo

0.71±0.07

0.62±0.07

Main statistical

Condition

0.345

0.092

effects and

Region

0.534

0.764

Condition*Region

0.920

0.772

Non-failing

Heart failure

interaction
(p values)
Protein contents are expressed in arbitrary units and were calculated by
normalizing to data obtained for each protein from a non-failing sub-epicardial
sample that was loaded onto every gel as a control, and corrected for the initial
weight of the original tissue sample.
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Table 4.4. Phosphorylation of selected sarcomeric proteins in non-failing
and failing tissue.
Phospho

Phospho

Phospho

cMyBP-C

cTnT

MLC-1

Epi

1.03±0.09

1.24±0.33

1.02±0.14

Mid

1.05±0.1

1.59±0.30

1.26±0.18

Endo

0.95±0.1

1.77±0.47

1.17±.0.11

Epi

0.79±0.05

1.91±0.46

1.34±0.19

Mid

0.77±0.06

1.68±0.39

1.34±0.26

Endo

0.86±0.16

2.16±0.49

1.52±0.24

Main statistical

Condition

0.094

0.53

0.367

effects and

Region

0.999

0.237

0.345

Condition *Region

0.554

0.484

0.457

Non-failing

Heart failure

interaction
(p values)
Phosphorylation levels are expressed in arbitrary units and were calculated
by normalizing to data obtained for each protein from a non-failing subepicardial sample that was loaded onto every gel as a control.
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Table 4.5. Site-specific phosphorylation of cMyBP-C at Ser273 and Ser282 in
non-failing and failing tissue.
PSer273

PSer282

cMyBP-C

cMyBP-C

Epi

1.38±0.28

1.01±0.17

Mid

1.39±0.35

1.01±0.14

Endo

1.38±0.35

1.01±0.21

Epi

1.31±0.27

0.97±0.08

Mid

1.35±0.27

0.94±0.07

Endo

1.03±0.16

0.97±0.08

Main statistical

Condition

0.685

0.76

effects and

Region

0.406

0.96

Condition *Region

0.428

0.900

Non-failing

Heart failure

interaction
(p values)
Phosphorylation levels are expressed in arbitrary units and
were calculated by normalizing to data obtained for each
protein from a non-failing sub-epicardial sample that was
loaded onto every gel as a control.
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Table 4.6. Statistically significant linear relationships between ktr and
biochemical data.
Biochemical variable

r

p value

Myosin

0.402

0.006

Actin

0.367

0.012

Actinin

0.290

0.045

MLC-2

0.535

<0.001

Phospho Desmin

0.425

0.031

Phospho cTnI

0.298

0.039
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Table 4.7. Statistically significant linear relationships between functional and
biochemical data.
Biochemical variable

Functional parameter

r

p value

cTnI

Maximum force

0.291

0.045

Actin

Maximum force

0.027

0.034

Phospho cMyBP-C

pCa50

-0.450

0.001

Phospho MLC-1

Vmax

-0.287

0.048

PSer273 cMyBP-C

Vmax

0.396

0.023

PSer282 cMyBP-C

Vmax

0.396

0.023

PSer23/24-cTnI

Passive stiffness

0.390

0.025

PSer23/24-cTnI

Passive force

0.390

0.006
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Figure 4.1. Mechanical records.
Superposed force and length records obtained during force-velocity experiments
performed with a representative preparation isolated from the mid-myocardium of
A) a non-failing heart and B) a failing heart (Force-velocity and force-power
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curves from these records are shown in Figure (4.2). The left hand shows the xaxis time-scale for the complete experiments. The right hand side shows the
expanded x-axis time-scale for the same experiments.
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Figure 4.2. Transmural heterogeneity of power output is reduced in heart
failure.
A) Representative force-velocity and force-power curves measured using
individual preparations from the sub-epicardial, mid-myocardial, and subendocardial regions of the left ventricle of one non-failing (NF, left) and one
failing (HF, right) heart. B) Symbols show the mean of the power outputs
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measured from 2 or 3 preparations from each region for each heart. In this figure,
and in all similar panels, thin lines join data points from the same heart. Thick
bars show the mean data for the region. The text above the plot shows p values
for the main statistical effects. Significant differences between regions, tested
separately for non-failing and failing hearts, are listed in the inset box. Significant
differences due to heart failure, tested separately for each region, are indicated
by asterisks (* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001).
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Figure 4.3. Transmural heterogeneity is reduced in heart failure with
isometric force but not with maximum shortening velocity.
A) Symbols show the mean of the maximum isometric forces measured from 2 or
3 preparations from each region for each heart. B) Symbols show the mean of
the maximum shortening velocities measured from 2 or 3 preparations from each
region for each heart.
93

Figure 4.4. Transmural variation in Ca2+ sensitivity is disrupted in heart
failure.
A) Mean values of normalized isometric tension plotted against pCa
(= -log10[Ca2+]) for preparations from the three transmural regions of non-failing
(left) and failing (right) hearts. Circles, squares, and triangles show data for subepicardial, mid-myocardial, and sub-endocardial preparations respectively. B)
Symbols show the mean of the pCa50 values measured using 2 or 3 preparations
from each region for each heart.
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Figure 4.5 Relative short-range stiffness depends on heart failure status.
A) Short-range stiffness and B) relative short-range force measured in pCa 4.5
solution. Stiffness values are expressed as Young’s Moduli and were calculated
by fitting regression lines to the force responses measured during 4% length
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changes imposed at a speed of 0.12 l0 s-1. In both plots, symbols show the mean
data value measured from 2 or 3 preparations from each region for each heart.
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Figure 4.6. Rate of tension redevelopment dependence on the
concentration of calcium.
ktr plotted as a function of relative isometric tension for A) non-failing samples
and B) failing samples. Symbols show the mean of the ktr values measured using
2 or 3 preparations from each region for each heart in different pCa solutions
plotted against relative isometric tension. The relative tension in pCa 4.5 solution
was defined as 1.
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Figure 4.7 Rate of tension redevelopment (ktr) does not depend on heart
failure status.
Symbols show the mean of the ktr measured from 2 or 3 preparations from each
region for each heart in A) pCa 4.5 and B) pCa 5.7.
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Figure 4.8. Representative images of myocardial sections from one nonfailing and one failing heart stained with picrosirius red.
Red staining indicates collagen. Yellow staining shows non-fibrotic tissue.

99

Figure 4.9. Collagen content is elevated in heart failure and is greatest in
mid-myocardial tissue.
A) Symbols show the mean collagen to tissue ratio measured from 1-6 sections
from each region for each heart. B) Actin and C) myosin contents (determined by
Lowry protein assays and gel electrophoresis) plotted against the collagen to
tissue ratios from panel B. A.U. stands for arbitrary units. Symbols follow the
same shape and color conventions as in panel B. The plots also show the best-fit
straight lines determined by linear regression and the corresponding p and r
values.
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Figure 4.10. Broadrange gel stained for phosphorylated and total
sarcomeric proteins.
Two images of a single representative gel stained with Pro-Q Diamond (left) and
SYPRO Ruby (right). The Pro-Q Diamond stain is more sensitive to
phosphoproteins while SYPRO Ruby indicates total protein content.
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Figure 4.11. cTnI content decreases with heart failure and phospho cTnI
depends on transmural region.
A) Symbols show the relative content of cTnI for each region for each heart using
SYPRO Ruby stain for total protein. B) Symbols show the mean Phospho cTnI
measured for each region for each heart using Pro-Q Diamond (phosphosensitive stain). A.U. stands for arbitrary units.
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Figure 4.12. PSer23/24 cTnI is reduced in heart failure.
A) Representative immunoblots showing total cTnI and PSer23/24 cTnI for nonfailing and failing hearts. B) Symbols show the mean PSer23/24 cTnI measured
for each region for each heart. A.U. stands for arbitrary units
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Figure 4.13. Desmin content increases and its phosphorylation decreases
with heart failure
A) Symbols show the relative content of desmin for each region for each heart
using SYPRO Ruby stain for total protein. B) Symbols show the mean phospho
desmin measured for each region for each heart using Pro-Q Diamond
(phosphor-sensitive stain). A.U. stands for arbitrary units.
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Figure 4.14. The relative content of the N2BA isoform of titin is increased in
heart failure.
A) Titin gels stained with Pro-Q Diamond (left) and SYPRO Ruby (right). The
figure shows lanes collated from several gels. The Pro-Q Diamond stain is
sensitive to phosphoproteins while SYPRO Ruby indicates total protein content.
B) Symbols show the relative content of the N2BA isoform for each region for
each heart. A.U. stands for arbitrary units. C) As for panel B but showing the
relative content of phosphorylated N2BA protein.
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Figure 4.15. PSer302 cMyBP-C depends on transmural region.
A) Representative immunoblots showing total cMyBP-C and PSer302 cMyBP-C
for non-failing and failing hearts. B) Symbols show the mean PSer302 cMyBP-C
measured for each region for each heart. A.U. stands for arbitrary units.
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Figure 4.16. Statistically significant relationships between maximum power
and biochemical data.
Each panel shows the relationship between maximum power and a selected
biochemical property (for example, actin content). The y coordinate of each
symbol indicates the mean value of maximum power measured from 2 or 3
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preparations from each region for each heart. The x coordinate of each symbol
shows the result of the biochemical assay performed using the matching sample.
The plots also show the best-fit straight lines determined by linear regression and
the corresponding p and r values. Table S4 provides r and p values for additional
relationships that had p values less than 0.05.
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Figure 4.17. Statistically significant relationships between rate of tension
redevelopment and biochemical data.
Each panel shows the relationship between ktr and a selected biochemical
property (for example, actin content). The y coordinate of each symbol indicates
the mean value of ktr measured from 2 or 3 preparations from each region for
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each heart. The x coordinate of each symbol shows the result of the biochemical
assay performed using the matching sample. The plots also show the best-fit
straight lines determined by linear regression and the corresponding p and r
values. Table 6 provides r and p values for additional relationships that had p
values less than 0.05.
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Figure 4.18. Contractile function is reduced with decrease in actin content.
A) Maximum Force and B) Maximum Power plotted against the actin content. C)
Maximum Force and D) Maximum Power plotted against the myosin content.
Protein content was determined by Lowry protein assays and corrected for initial
weight of the tissue (Table S3 and gel electrophoresis Figure 13A). A.U. stands
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for arbitrary units. The plots show the best-fit straight lines determined by linear
regression and the corresponding p and r values.
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Figure 4.19. Passive force and passive stiffness do not depend on heart
failure status.
A) Passive force and B) passive stiffness measured in pCa 9.0 solution. In both
plots, symbols show the mean data value measured from 2 or 3 preparations
from each region for each heart.
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Figure 4.20. Ca2+ sensitivity of non-failing samples depended on the
phosphorylation of cMyBP-C.
Ca2+ sensitivity of non-failing samples correlated significantly with A) total
phosphorylation of cMyBP-C and B) site-specific phosphorylation of cMyBP-C at
Ser302. A.U. stands for arbitrary units. The plots show the best-fit straight lines
determined by linear regression and the corresponding p and r values.
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Figure 4.21. Site-specific phosphorylation of cTnI at Ser23/24 correlated
with phosphorylation of cMyBP-C.
A) Total phosphorylation and B) site-specific phosphorylation of cTnI at Ser23/24
correlations with total phosphorylation of cMyBP-C. A.U. stands for arbitrary
units. The plots show the best-fit straight lines determined by linear regression
and the corresponding p and r values.
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Figure 4.22. cTnI content is reduced in ischemic heart failure.
Symbols show the mean cTnI content measured for each region for failing hearts
with ischemic disease (left) and non-ischemic disease (right).
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Figure 4.23. MHC isoforms.
β-MHC bands seen in the non-failing and failing samples from the transmural
regions. The human atrial samples have both the α- and β-MHC resolved.
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Figure 4.24. cMyBP-C strongly correlated with both MLC-1 and MLC-2.
Significant correlations between cMyBP-C and A) MLC-1 and B) MLC-2.

Copyright © Premi Haynes 2014
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Chapter 5. Discussion

5.1. Overall Conclusions
The heart can fail as pump due to decreased contractility or diminished
ventricular relaxation. One or both of these impairments can get progressively
worse and lead to irreversible heart failure. In this dissertation, we sought to
identify transmural cellular level contractile mechanisms that are modified in the
left ventricle just prior to the onset of heart failure and in end-stage heart failure.
This dissertation demonstrates that normal left ventricles exhibit transmural
heterogeneity in cellular level contractile properties and that with aging and heart
failure there are region-specific changes in cellular level contractile mechanisms.
The aging F344 rat study detailed in Chapter 3 revealed that the 22-month old
animals exhibited a region-specific decrease in phosphorylation of cTnI in the
sub-epicardial samples when compared to the mid-myocardial and subendocardial samples of the same age. This molecular modification may
contribute to the slowed relaxation of sub-epicardial myocytes in the 22-month
old animals. We were thus able to identify a molecular level modification, which
potentially contributes to diastolic dysfunction before the onset of aging
associated heart failure.
The human heart failure study detailed in Chapter 4 revealed that the contractile
properties of human hearts exhibit transmural variation in non-failing organs, and
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that heart failure alters the transmural pattern as well as depressing myocardial
function. These new results show that contractile properties are heterogenous in
non-failing left ventricles and that there are region-specific modifications in
contractile properties with heart failure. These new results help to explain why in
vivo shortening of the middle transmural region is a better predictor of
cardiovascular death than traditional global measures of ventricular function.

5.2. Limitations of the studies in this dissertation

5.2.1. Use of rodent model
Even though rodent models are very useful in understanding mechanisms of
cardiac dysfunction they have some disadvantages like differential expression of
ion channel, Ca2+ handling proteins and sarcomeric proteins compared to
humans 68, 149, 150. In Chapter 3, we discussed that 6-month old rodents express
~70 % of α-MHC (Figure 3.5). With age 65 and disease 151 the rodents switch to a
greater proportion of the β-MHC isoform. Furthermore, the increase in the
proportion of β-MHC isoform slows cross bridge kinetics and can affect both
contraction 152 and relaxation properties 68. Even though there is a functional
effect of the β-MHC isoform shift with aging and disease in rodents, this may not
be the case in humans. Non-failing human hearts already express ~ 90-100% βMHC isoform 116, 142 (Figure 4.23) and therefore the shift in isoform if any will be
very small with human heart failure 123. This means that there are other
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mechanisms that influence kinetics in humans and it would be hard to tease out
these mechanisms using animal models because of the dominating effect of βMHC isoform shift on kinetics.

5.2.1.1. Biochemical analysis
One of the limitations of the aging F344 rat study was that the n=3 animals in
each age group for the biochemical analysis. This meant that the study may have
been under powered. Future studies may require increase in the number of
animals.

5.2.2. Use of human tissue
Humans are genetically different from each other and come from different
environments. However, it is important to note that the use of human tissue
provides data that is more clinically relevant than some animal studies and is
thus arguably of more translational relevance.
We had logistical difficulty in obtaining the human tissue samples that were age
and gender matched to the donors and patients (Table 2.2). As discussed in
section 2.1.2.2, the mean age of the patients with heart failure was 49 (range 20
to 65) while that of the organ donors was 35 (range 18 to 59). Females donated
20% of the failing hearts and 50% of the non-failing organs. We performed
regression analyses and showed that the key contractile properties reported in
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this work did not vary with age (Figure 5.1). Furthermore, we showed that there
was no significant interaction between gender and condition in our study
(Figure 5.2) for the key contractile properties suggesting that heart failure was
not gender dependent.
We also investigated the effect of β blocker on heart failure patients because βadrenergic stimulation activates an important signaling pathway that can regulate
various contractile proteins 63, 110, 153. We did not find any significant difference in
the key contractile properties measured and the effect of β-blocker (Figure 5.3).
It is possible that ischemic and non ischemic heart failure produce distinct
changes in contractile function (Tables 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9
and 5.10 and Figures 4.22 and 5.4). Due to the small sample size (n=5 in both
heart failure groups), tests comparing ischemic and non-ischemic samples had
limited statistical power. The results from Tables 5.9 and 5.10 could be
interpreted as suggesting that failing non ischemic tissue has worse contractile
function than failing ischemic tissue. It would be interesting to follow up on these
results in future work using larger numbers of hearts.
All of the organ donors in this study had been treated in Intensive Care Units
before the determination of brain death and some had comorbidities such as
diabetes and/or hypertension. Therefore, it is unclear whether the non-failing
hearts are truly representative of healthy organs. However, none of the donors
had a prior history of ventricular dysfunction and the hearts used in this work are
the best controls that are available.
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5.2.2.1. Permeabilized samples
We performed functional measurements using chemically permeabilized
multicellular preparations. These biospecimens were optimal for testing
myofibrillar-level function and for investigating the effects of the extracellular
matrix on passive mechanical properties. However, additional experiments using
enzymatically isolated cells that are still electrically excitable could also have
investigated potential transmural variation in calcium handling (similar to the
functional experiments done in Chapter 3 65) 154 and mitochondrial function 155.
These measurements cannot be performed once the membranes have been
permeabilized.

5.3. Linking in vitro mechanics to in vivo function

5.3.1. Pressure-volume relationship
The pressure-volume loop (PV) gives in vivo information about left ventricular
performance during a single cardiac cycle. The PV loop can be divided into 4
phases (Figure 5.5A). In phase “a” (diastole) the mitral valve opens and
ventricular filling occurs. In phase “b” (systole) the mitral valve closes and
isovolumic contraction occurs where the left ventricular pressure rises and the
volume remains the same. In phase “c” (systole) the aortic valve opens after the
left ventricular pressure exceeds the aortic pressure, which then leads to
ejection. During ejection the heart has to perform external work against an
124

afterload. In phase “d” (diastole), the aortic valve closes after the ventricular
pressure becomes lower than the aortic pressure and isovolumic relaxation
occurs. The ventricular pressure declines further and the ventricle begins to relax
without a change in volume. PV loops can therefore yield information about the
work done by the ventricle. Detrimental changes to any of these 4-phases can
indicate cardiac dysfunction.

5.3.2. Permeabilized preparations-in vitro mechanics
The cellular level contractile properties investigated in this dissertation gives an
in vitro index of systolic and diastolic function. In the human heart failure study
detailed in Chapter 4, we measured active and passive mechanical properties of
multicellular preparations, which were representative of the myocytes linked with
the connective tissue in the left ventricle. Figure 5.5 summarize some of the in
vitro parameters investigated in this study that we can compare to the different
phases of the PV loop. For example, the in vitro measure of force and power
gives us information about phase “c” (ejection) of the PV loop. In our study, there
was an ~20% decrease in power in heart failure samples (Figure 4.2) and this in
vitro measure indicates systolic dysfunction at the cellular level. Similarly, we did
not see a significant difference in the rate of tension redevelopment in failing
hearts (Figure 4.7) which in our study may potentially be an index of rate of
pressure development (dp/dt).
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It should be noted that the extrapolation of the in vitro mechanical properties to
the PV loop is simplistic because the PV loop is indicative of global left
ventricular function. However, the in vitro measurements are representative of
the mechanical behavior of the sarcomeres and connective tissue that contribute
to the various phases of the PV loop and can therefore be extremely useful to
identify molecular and cellular level modifications.

5.4. Sarcomere level therapies for heart failure
Modifications to sarcomeric proteins can lead to pump dysfunction 63. In this
dissertation we reported posttranslational modifications to sarcomeric proteins,
isoform switch and decrease in the relative content of sarcomeric proteins in
aging (Chapter 3) and in heart failure (Chapter 4).
One of the major modifications that can regulate sarcomere function is
phosphorylation of sarcomeric proteins like cTnI, cMyBP-C and titin. Studies
have shown that PKA, PKC and PKG are the main kinases that phosphorylate
these proteins 63, 126, 156. Changes to the phosphorylation level of sarcomeric
proteins can alter contractile function. For example, in heart failure, there is a
decrease in β2 stimulations either due to desensitization of the β2 receptors or
decrease in the content of the receptors themselves 157. Activation of the β2adrenergic receptor signaling leads to an increase in cAMP, which in turn
activates PKA. PKA can then phosphorylate sarcomeric proteins including cTnI,
cMyBP-C and Titin 158. In the aging F344 rat study we saw a decrease in cTnI
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phosphorylation in the sub-epicardial cells of 22-month old F344 rats (Figure 3.7)
and in the human heart failure study we saw a site-specific decrease in
phosphorylation of cTnI at Ser 23/24 in failing hearts (Figure 4.12). In the aging
F344 rat study phosphorylation of cTnI was linked to slowed relaxation and in the
human heart failure study there was a significant novel correlation between sitespecific phosphorylation of cTnI at Ser 23/24 and passive stiffness (Table 4.7).
These results from both rodent and human studies (Chapter 3 and 4) make
phosphorylated cTnI a potential contributor to relaxation and therefore a
therapeutic target for diastolic dysfunction.
Sarcomere-level interventions could potentially be effective treatment for heart
failure. For example, a cardiac specific myosin activator molecule 159 is in phase
II clinical trials and is being evaluated for acute and chronic systolic heart failure.
Its mechanism of action allows the myosin cross bridges to strongly bind to actin
and stay bound for a longer duration 160. In the human heart failure study for
example, we not only saw a significant decrease in cTnI content in human heart
failure (Figure 4.11) we also saw a significant correlation between power and
relative cTnI content (Figure 4.16A) which is a potential sarcomeric protein that
can be targeted to improve cardiac function.

5.5. Importance of transmural heterogeneity in the ventricular wall
Anatomical location is sometimes ignored when studying the left ventricle
because it is assumed that it is a homogenous structure. However, in Chapter 1
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(section 1.1), we discussed that the ventricular wall is made up “layers” of muscle
with changing fiber angles 1-4, 6. There are known transmural differences in action
potential morphologies in human and animal hearts 42-44 and few studies in
animals have shown differences in contractile properties 46, 47, 64, 101. Our study,
for the first time showed differences in contractile properties across the
ventricular wall in non-failing and failing human myocardium (Chapter 4) and a
region-specific molecular modification in aging F344 rats (Chapter 3).

5.5.1. The mid-myocardium in the failing human heart
Ingels, 1997 10, laid down several working hypothesis to explain the coupling
between the myocardial fiber architecture and left ventricular function. He utilized
LaPlace’s law (P=Tw/r where T is wall tension; w is wall thickness and r is radius
of the cavity) and proposed that the mid-myocardial circumferential fibers are
optimal to develop pressure because they have a minimum radius of curvature
when compared to the spiral sub-endocardial fibers which are better suited to
maximize ejection fraction 10. In the human heart failures study we saw a
significant decrease in force and power and increased fibrosis in the midmyocardial samples of the failing hearts (Figure 4.2, 4.3A, 4.8 and 4.9). These
region-specific changes could contribute to the decrease in global ventricular
function in patients in end-stage heart failure because the mid-myocardial
circumferential fibers necessary to generate the required pressure are
dysfunctional.
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5.5.2. The mid-myocardial region of non-failing human hearts
The mid-myocardial samples from the non-failing human hearts exhibited
increase in power and force (4.2 and 4.3A) compared to the sub-epicardial and
sub-endocardial samples. There are two potential reasons as to why the
myocytes from the mid-myocardial region have different contractile
properties, 1) the environment that these myocytes are located in in vivo make
them different and/or 2) myocytes from the mid-myocardial region are specialized
myocytes.

5.5.2.1. Mechanosensitive pathways
The mid-myocardial fibers are arranged circumferentially in the left ventricle while
the sub-epicardial and the sub-endocardial fibers are more longitudinally
arranged 5. This means that the myocytes in the mid-myocardial region
potentially undergo different mechanical stress and strain stimuli than the
myocytes in the sub-epicardial and sub-endocardial regions. Studies have shown
that longitudinal vs. tranverse stretch can bring about different anistropic
(dependent on direction) changes in myocytes and lead to differential
upregulation of sarcomeric proteins 161-163. The major signal transduction
pathways that are activated by mechanical stimuli are mitogen-activated protein
kinase (MAPK) pathway, the Janus-associates kinases/signal transducers and
activators of transcription (JAK/STAT) 164 and/or the Ca2+/calmodulin-dependent
phosphatase calcineurin 165. Particularly, z-disk proteins and titin have been
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implicated in being able to sense changes in cell stress and strain, which then
leads to transcriptional regulation 166, 167.
Further studies need to be done in order to understand the role of these
pathways in non-failing human hearts.

5.5.2.2. M cells
There is some evidence of the existence of specialized population of myocytes in
the mid-myocardium known as M cells. These cells have been extensively
studied due to their distinct electrophysiological properties and are described to
be a hybrid of purkinje and ventricular cells 168. Specifically, M cells have a
characteristically prolonged action potential duration when compared to the subepicardial and sub-endocardial myocytes 42, 168 and are present in different
species including humans 169, 170 41. A recent study demonstrated that M cells
were present in island like cluster in non-failing human hearts but were not found
in the failing human heart 42. The M cells may have distinct electrophysiological
properties but further studies need to be done to investigate if they also have
distinct contractile properties.
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5.6. Application of this work
The findings from these studies have broader implication in three major
cardiovascular fields that strive for patient-specific treatments- mainly cardiac
imaging, ventricular finite element modeling and stem cell research.

5.6.1. Imaging studies
Both the aging F344 rat study and the human heart failure study revealed regionspecific modifications in aging and failing left ventricles. The aging F344 rat study
made use of imaging tools and demonstrated that ventricular torsion changes
with age 65 and previous clinical studies have shown that shortening of the midmyocardial region in a better predictor of cardiovascular outcomes than
shortening of the endocardial region and ejection fraction 26-30. All of these
studies point out that global measures of ventricular function (ejection fraction)
may not be sufficient for patient prognosis. With the increased use of MRI
(magnetic resonance imaging) it will become more feasible to isolate regionspecific changes that occur in dysfunctional myocardium 171.

5.6.2. Ventricular modeling
Computational models of the human hearts use in vivo imaging data to make
predictions of myocardial contractility in patients with damaged myocardium 172.
But it has become more evident that multiscale modelling maybe more accurate
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in predicting ventricular function because it takes into account cellular level
contractile properties 173. Our data helps to fill this gap as we have transmural
cellular level contractile data in rodents and humans.

5.6.3. Stem cell therapies
In the past several years many advances have been made to utilize stem-cell
therapy for patients with heart failure. The basic idea is to replace and/or repair
injured myocardium by delivering stem cells to the heart to improve its function.
One of the challenges has been to find the best method of stem cell delivery that
will reach the target 174. There are three main ways to deliver stem cells, 1)
systemic intravenous infusion, 2) intracoronary infusion, and 3) direct
intramyocardial injection (for example-during a coronary bypass graft). Each of
these delivery systems have their own advantages and disadvantages. Even
though intramyocardial injections are more invasive than other delivery systems,
studies have shown that the hearts are able to retain stem cells better with this
approach compared to the other 2 approaches 175-178.
Our study showed that the mid-myocardial samples from the non-failing hearts
generate more power and more force than sub-epicardial and sub-endocardial
samples. Furthermore, the mid-myocardial samples produced the least amount
of force than sub-epicardial and sub-endocardial samples of the failing hearts
(Figure 4.2 and 4.3A). This means that delivering stem cells to the midmyocardium could be especially beneficial to improve systolic function.
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Specifically, in patients with non ischemic heart disease who donot have a
targeted region unlike patients with myocardial infract whose infract region may
be the target for stem cell delivery.

5.7. Overall perspective
Complementary studies in human tissue and animal models needs to be
performed in order to prevent and cure human heart failure 179. One way to
approach this is to systematically investigate the molecular level modifications
that occur with heart failure in human tissue. These modifications should then be
correlated with functional parameters that strongly predict them. The molecular
mechanism should then be tested in other systems like transgenic and knockout
animal models or cell cultures. Integration of all these system is key. In this
dissertation we have tried to accomplish this method.
Finally, we have shown that there are contractile transmural heterogeneities
across the ventricular wall in normal myocardium and there are region-specific
modifications that occur with aging and heart failure. These cellular level
modifications can contribute to organ level function and should be taken into
account.
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Table 5.1. Functional contractile properties in non ischemic and ischemic
tissue.
Maximum

Maximum

Maximum

Power

Force

Velocity

(μW mg-1)

(kN m-2)

(mL s-1)

Epi

0.37±0.04

9.79±1.10

1.05±0.07

Mid

0.34±0.03

7.69±0.68

1.09±0.09

Endo

0.31±0.02

9.33±1.09

0.93±0.05

Epi

0.43±0.03

12.41±0.83

1.00±0.05

Mid

0.40±0.04

9.90±0.63

1.01±0.07

Endo

0.36±0.05

9.38±1.09 §

1.06±0.09

Main statistical

Condition

0.348

0.228

0.999

effects and

Region

0.045*

0.007**

0.773

Condition *Region

0.845

0.145

0.334

Non ischemic

Ischemic

interaction
(p values)
Protein contents are expressed in arbitrary units and were calculated by normalizing to
data obtained for each protein from a non-failing sub-epicardial sample that was loaded
onto every gel as a control. Difference between main statistical effects and interaction:
p<0.05= * and p<0.01=**. Different from the sub-epicardial region of the same condition:
p<0.05= §.
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Table 5.2. Functional contractile properties in non ischemic and ischemic
tissue.
Maximum

Maximum

Power

Force

(μW mg-1)

(kN m-2)

pCa50

Epi

0.37±0.04

9.79±1.10

5.68±0.02

Mid

0.34±0.03

7.69±0.68

5.70±0.02

Endo

0.31±0.02

9.33±1.09

5.65±0.05

Epi

0.43±0.03

12.41±0.83

5.69±0.03

Mid

0.40±0.04

9.90±0.63

5.76±0.05

Endo

0.36±0.05

9.38±1.09 §

5.72±0.04

Main statistical

Condition

0.348

0.228

0.535

effects and

Region

0.045*

0.007**

0.140

Condition *Region

0.845

0.145

0.286

Non ischemic

Ischemic

interaction
(p values)
Protein contents are expressed in arbitrary units and were calculated by normalizing to
data obtained for each protein from a non-failing sub-epicardial sample that was loaded
onto every gel as a control. Difference between main statistical effects and interaction:
p<0.05= * and p<0.01=**. Different from the sub-epicardial region of the same condition:
p<0.05= §.
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Table 5.3. Functional passive properties in non ischemic and ischemic
tissue.
Passive Force

Passive Stiffness

(kN m-2)

(kN m-2)

Epi

0.84±0.08

25.14±4.45

Mid

0.60±0.07

19.72±3.53

Endo

0.84±0.11

33.26±6.57

Epi

1.09±0.13

53.20±12.78 †

Mid

0.75±0.14

28.88±12.10

Endo

1.01±0.15

32.54±5.87

Main statistical

Condition

0.080

0.166

effects and

Region

0.030*

0.187

interaction (p values)

Condition *Region

0.910

0.209

Non ischemic

Ischemic

Protein contents are expressed in arbitrary units and were calculated by normalizing
to data obtained for each protein from a non-failing sub-epicardial sample that was
loaded onto every gel as a control. Difference between main statistical effects and
interaction: p<0.05= *. Different between the same regions of non ischemic and
ischemic group: p<0.05= †.
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Table 5.4. Content of selected sarcomeric proteins in non ischemic and
ischemic tissue.
cMyBP-C

cTnT

Actinin

Epi

0.88±0.08

1.09±0.52

0.95±0.10

Mid

1.1±0.33

1.26±0.58

1.22±0.21

Endo

1.00±0.13

1.22±0.57

1.08±0.12

Epi

1.19±0.08

1.11±0.36

1.17±0.08

Mid

1.08±0.05

1.68±0.39

1.05±0.03

Endo

0.76±0.15 §

1.00±0.43

0.89±0.15

Main

Condition

0.904

0.853

0.732

statistical

Region

0.084

0.937

0.402

Condition *Region

0.025*

0.932

0.146

Non
ischemic

Ischemic

effects and
interaction
(p values)
Protein contents are expressed in arbitrary units and were calculated by
normalizing to data obtained for each protein from a non-failing sub-epicardial
sample that was loaded onto every gel as a control. Difference between main
statistical effects and interaction: p<0.05= *. Different from the sub-epicardial
region of the same condition: p<0.05= §.
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Table 5.5. Content of selected sarcomeric proteins in non ischemic and
ischemic tissue.
MLC-1

MLC-2

Epi

0.91±0.10

0.96±0.10

Mid

1.20±0.13

1.21±0.18

Endo

0.98±.0.16

1.12±0.21

Epi

1.33±0.10

1.33±0.16

Mid

1.17±0.14

1.10±0.12

Endo

0.91±0.24 §

0.90±0.24

Main

Condition

0.564

0.964

statistical

Region

0.126

0.496

Condition *Region

0.084

0.096

Non
ischemic

Ischemic

effects and
interaction
(p values)
Protein contents are expressed in arbitrary units and were
calculated by normalizing to data obtained for each protein
from a non-failing sub-epicardial sample that was loaded onto
every gel as a control. Difference between main statistical
effects and interaction: p<0.05= *. Different from the subepicardial region of the same condition: p<0.05= §.
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Table 5.6. Content of Myosin Heavy Chain (MHC) and Actin in non ischemic
and ischemic tissue.
MHC

Actin

Epi

0.70±0.04

0.64±0.04

Mid

0.75±0.05

0.61±0.04

Endo

0.81±0.04

0.66±0.05

Epi

0.78±0.02

0.68±0.02

Mid

0.63±0.05

0.54±0.03

Endo

061±0.13 †

0.58±0.14

Main statistical

Condition

0.217

0.608

effects and

Region

0.733

0.515

Condition*Region

0.124

0.574

Non ischemic

Ischemic

interaction
(p values)
Protein contents are expressed in arbitrary units and were calculated by
normalizing to data obtained for each protein from a non-failing sub-epicardial
sample that was loaded onto every gel as a control, and corrected for the initial
weight of the original tissue sample. Different between the same regions of non
ischemic and ischemic group: p<0.05= †.
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Table 5.7. Phosphorylation of selected sarcomeric proteins and residues in
non ischemic and ischemic tissue.
Phospho

Phospho

Phospho

cMyBP-C

cTnT

MLC-1

Epi

0.75±0.10

2.50±0.89

0.91±0.10

Mid

0.84±0.07

1.93±0.64

1.20±0.13

Endo

0.73±0.10

1.82±0.47

0.98±0.16

Epi

0.83±0.03

1.70±0.45

1.33±0.10

Mid

0.70±0.11

1.43±0.50

1.17±0.14

Endo

0.10±0.32

2.50±0.89

0.91±0.24 §

Main

Condition

0.678

0.921

0.564

statistical

Region

0.749

0.370

0.126

Condition *Region

0.337

0.168

0.084

Non
ischemic

Ischemic

effects and
interaction
(p values)
Phosphorylation levels are expressed in arbitrary units and were calculated
by normalizing to data obtained for each protein from a non-failing subepicardial sample that was loaded onto every gel as a control. Difference
between main statistical effects and interaction: p<0.05= *. Different from
the mid-myocardial region of the same condition: p<0.05= ‡. Different from
the sub-epicardial region of the same condition: p<0.05= §.
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Table 5.8. Phosphorylation of selected sarcomeric proteins and residues in
non ischemic and ischemic tissue.
PSer273

PSer282

cMyBP-C

cMyBP-C

Epi

0.94±0.28

0.88±0.10

Mid

1.25±0.44

0.91±0.11

Endo

0.80±0.17

0.88±0.10

Epi

1.80±0.49

1.09±0.11

Mid

1.49±0.35

0.99±0.10

Endo

1.35±0.21

1.10±0.09 ‡

Main

Condition

0.240

0.279

statistical

Region

0.187

0.302

Condition *Region

0.247

0.043*

Non
ischemic

Ischemic

effects and
interaction
(p values)
Phosphorylation levels are expressed in arbitrary units and
were calculated by normalizing to data obtained for each
protein from a non-failing sub-epicardial sample that was
loaded onto every gel as a control. Difference between main
statistical effects and interaction: p<0.05= *. Different from the
mid-myocardial region of the same condition: p<0.05= ‡.
Different from the sub-epicardial region of the same condition:
p<0.05= §.
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Table 5.9. Functional contractile properties in non-failing and ischemic
tissue.
Maximum Power

Maximum Force

(μW mg-1)

(kN m-2)

pCa50

Epi

0.46±0.03

10.96±0.74

5.619±0.01

Mid

0.59±0.06§

14.30±1.33§

5.67±0.02

Endo

0.46±0.04‡

11.47±0.86‡

5.69±0.02§

Epi

0.43±0.03

12.41±0.83

5.69±0.03

Mid

0.40±0.04†

9.90±0.63†

5.76±0.05§

Endo

0.36±0.05

9.38±1.09§

5.72±0.04

Main statistical

Condition

0.080

0.230

0.251

effects and

Region

0.057

0.110

0.001

interaction (p values)

Condition *Region

0.132

0.004

0.366

Non-failing

Ischemic

Effect of ischemic status on region: † p<0.05. Different from the sub-epicardial region of the
same condition: § p<0.05. Different from the mid-myocardial region of the same condition: ‡
p<0.05.
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Table 5.10. Functional contractile properties in non-failing and non ischemic
tissue.
Maximum Power

Maximum Force

(μW mg-1)

(kN m-2)

pCa50

Epi

0.46±0.03

10.96±0.74

5.619±0.01

Mid

0.59±0.06§

14.30±1.33§

5.67±0.02

Endo

0.46±0.04‡

11.47±0.86‡

5.69±0.02§

Epi

0.37±0.04

9.79±1.10

5.68±0.02

Mid

0.34±0.03†

7.69±0.68†

5.70±0.02

Endo

0.31±0.02†

9.33±1.09

5.65±0.05

Main statistical

Condition

0.009

0.040

0.717

effects and

Region

0.117

0.704

0.096

interaction (p values)

Condition *Region

0.091

0.004

0.004

Non-failing

Non ischemic

Effect of non ischemic status on region: † p<0.05. Different from the sub-epicardial region of
the same condition: § p<0.05. Different from the mid-myocardial region of the same condition:
‡ p<0.05.
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Figure 5.1. No statistically significant relationships between contractile
properties and age.
Each panel shows the relationship between a selected functional parameter and
age. The y coordinate of each symbol indicates the mean value of a functional
parameter measured from 2 or 3 preparations from each region for each heart.
The x coordinate of each symbol shows the age of the individual patient/donor.
The plots also show the best-fit straight lines determined by linear regression and
the corresponding p and r values.
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Figure 5.2. Contractile properties did not depend on gender.
Symbols show the mean of the A) Maximum Power, B) Maximum Force and C)
pCa50 measured from 4 or 6 preparations from each condition for each heart.
Thick bars show the mean data for the condition. The text above the plot shows p
values for the main statistical effects.
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Figure 5.3. Contractile properties did not depend on β-blocker.
Symbols show the mean of the A) Maximum Power, B) Maximum Force and C)
pCa50 measured from 4 or 6 preparations from each heart. Thick bars show the
mean data with and without β-blocker. The text above the plot shows p values for
the main statistical effect.
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Figure 5.4. Collagen content is increased in the mid-myocardium of
patients with ischemic and non-ischemic disease.
Symbols show the mean collagen to tissue ratio measured for each region for
failing hearts with ischemic disease (left) and non-ischemic disease (right). A.U.
stands for arbitrary units.
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Figure 5.5. Linking in vitro mechanics to in vivo function.
A) Schematic pressure-volume loop, B) Raw traces of the 3-stretch protocol, C)
Force-velocity curve and D) Force-Power curve. The top right panel shows
variables measured to assess ventricle function.
Copyright © Premi Haynes 2014
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